Consolidated Financial Statements Years Ended October 31, 2022 and 2021 (Stated in Canadian Dollars)



Consolidated Financial Statements

Years Ended October 31, 2022 and 2021

	Page
In demandent Anditon's Demant	1
Independent Auditor's Report	1
Consolidated Statements of Financial Position	4
Consolidated Statements of Operations and Comprehensive Loss	5
Consolidated Statements of Changes in Equity	6
Consolidated Statements of Cash Flows	7
Notes to Consolidated Financial Statements	8



INDEPENDENT AUDITOR'S REPORT

To the shareholders of

HERITAGE CANNABIS HOLDINGS CORP.

Opinion

We have audited the consolidated financial statements of Heritage Cannabis Holdings Corp. (the Company), which comprise the consolidated statement of financial position as at October 31, 2022, and the consolidated statements of operations and comprehensive loss, changes in equity and cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as at October 31, 2022 and its financial performance and its consolidated cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs).

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Matter

The consolidated financial statements of the Company for the year ended October 31, 2021 were audited by another auditor who expressed an unmodified opinion on those financial statements on May 10, 2022.

Material Uncertainty Related to Going Concern

We draw attention to Note 1 in the consolidated financial statements, which indicates that the Company incurred a comprehensive loss of \$23,937,773 during the year ended October 31, 2022 and, as of that date, the Company's accumulated deficit was \$114,808,267 and its negative operating cash flows were \$2,428,716. As stated in Note 1, these events or conditions, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Other Information

Management is responsible for the other information. The other information comprises the information, other than the consolidated financial statements and our auditor's report thereon, in the Management's Discussion and Analysis.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

We obtained Management's Discussion and Analysis prior to the date of this auditor's report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact in this auditor's report. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of expressing an
 opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



Auditor's Responsibilities for the Audit of the Consolidated Financial Statements - Cont'd.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The engagement partner on the audit resulting in this independent auditor's report is Bryan Haralovich.

Chartered Professional Accountants Licensed Public Accountants

Ottawa, Ontario February 23, 2023.

Consolidated Statements of Financial Position As at October 31, 2022 and October 31, 2021

(Stated in Canadian Dollars)

	,	As at		As at		
Notes	Oct	October 31, 2022		ober 31, 2021		
	\$	5,107,617	\$	3,763,577		
5		950,000		950,000		
		210,457		1,014,805		
25(a)		7,488,117		4,773,285		
6		16,788,609		16,124,241		
7		2,013,977		2,347,740		
8		-		259,481		
9		302,171		-		
16(b),22		-		48,831		
		32,860,948		29,281,960		
9		1,712,303		-		
10		799,812		438,678		
11				3,044,182		
12				44,253,279		
		, , , , , , , , , , , , , , , , , , ,		20,769,966		
	\$	78,412,192	\$	97,788,065		
22(a) 25(b)	¢	15 107 406	¢	7 705 161		
22(C),23(D)	Э		Э	7,785,461		
2(-)(')				276,032		
_				240,705		
				79,359		
		5,878		5,321		
		-		590,176		
17				-		
				8,977,054		
				729,744		
		16,815,481		10,836,359		
		-		15,940,000		
		,		1,478,469		
21				4,606,000		
		38,461,971		42,567,626		
				140,482,057		
				5,779,474		
11,25(c)(i)		109,403		(197,307		
		(114,808,267)		(91,538,667		
		39,950,221		54,525,557		
20		=		694,882		
		39,950,221		55,220,439		
	5 25(a) 6 7 8 9 16(b),22 9 10 11 12 13 22(c),25(b) 2(q)(i) 14 15 16 17 14 15 16 17 21	Notes Notes S 25(a) 6 7 8 9 16(b),22 9 10 11 12 13 \$ 22(c),25(b) \$ 2(q)(i) 14 15 16 17 14 15 16 17 21 18 19 11,25(c)(i)	Notes	South		

Going Concern (Note 1(a))

Commitments (Note 23)

Subsequent Events (Note 32)

The accompanying notes are an integral part of these consolidated financial statements.

Approved on behalf of the Board of Directors:

"Clint Sharples"	"David Schwede", CEO
Director	Director

Consolidated Statements of Operations and Comprehensive Loss

Years Ended October 31, 2022 and 2021

(Stated in Canadian Dollars)

	Notes	Years Ended	d October 31,			
		2022		2021		
Gross Revenue	27	\$ 41,996,297	\$	18,676,958		
Excise taxes		(12,429,912)		(4,617,828)		
Net Revenue		29,566,385		14,059,130		
Cost of Sales	6	21,599,867		13,492,997		
Gross Margin		7,966,518		566,133		
General and Administrative Expenses						
Advertising, travel and promotion		768,397		1,654,619		
Amortization and depreciation	6,12,13	3,732,493		5,223,667		
Management and consulting fees	22	1,097,624		2,034,610		
Occupancy, general and administrative		5,705,218		2,842,580		
Professional fees		947,258		1,060,650		
Share-based payments	18(b),19(b),22	770,095		692,816		
Salaries, wages and benefits	22	7,567,711		4,965,320		
		20,588,796		18,474,262		
Other Income (Expense)						
Interest and other income	9	172,987		121,591		
Interest and finance expense	14,15,17	(1,144,990)		(958,848)		
Share of loss from investment in associate	11	(135,211)		(235,393)		
Impairment of intangible assets and goodwill	12	(21,215,000)		(36,337,826)		
Unrealized gain on other investments	10(ii)(iii)	572,774				
Unrealized gain (loss) on contingent consideration payable	16	9,137,267		(3,514,865)		
Unrealized gain (1933) on contingent consideration payable Unrealized gain on derivative liabilities	17	214,323		236,772		
Loss on debt extinguishment	15(b),19(a)	(1,793,251)		(1,361,338)		
Impairment of inventories	13(b),13(a) 6	(1,793,231)		(513,137)		
_		(106 104)		(313,137)		
Impairment of deposit	10(i)	(106,104) (14,297,205)		(42,563,044)		
Loss Before Taxes		(26,919,483)		(60,471,173)		
Income tax recovery		, , ,				
Deferred income tax recovery	21	(2,675,000)		(3,018,960)		
		(2,675,000)		(3,018,960)		
Net Loss		\$ (24,244,483)	\$	(57,452,213)		
Other comprehensive income (loss) that may be reclassified to net loss						
Gain (loss) on foreign currency translation	11,25(c)(i)	306,710		(233,319)		
Comprehensive Loss		\$ (23,937,773)	\$	(57,685,532)		
Comprehensive Income (Loss) attributed to:						
Shareholders of the Company		\$ (24,837,930)	\$	(57,740,228)		
Non-controlling interest	20	900,157		54,696		
		\$ (23,937,773)	\$	(57,685,532)		
Weighted average number of outstanding shares, basic and diluted						
	24	872,786,254		697,447,550		
Basic and diluted loss per share	24	\$ (0.03)	\$	(0.08)		

The accompanying notes are an integral part of these consolidated financial statements.

HERITAGE CANNABIS HOLDINGS CORP. Consolidated Statements of Changes in Equity Years Ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

	Notes	Number of Shares	SI	nare Capital	Contributed Sur	olus •	Accumulated Other Comprehensive Income (Loss)		Retained Earnings Accumulated Deficit)	Non-controlling Interest	Total
				•		•	·		,		
Balance at October 31, 2020 Share-based payments - vesting of options Share-based payments - issuance of restricted	18(b),19(b)	496,136,722	\$	96,203,173		,218 ,123	\$ 36,012	2 \$	(34,031,758)	\$ 640,186	\$ 68,264,831 342,123
shares	18(b),19(c)	2,191,831		350,693		-	-		-	-	350,693
Restricted shares issued for debt and services	18(b)	2,884,797		342,142		_	_		_	_	342,142
Shares issued for debt and services	18(b)	3,308,933		228,218		_	-		_	_	228,218
Exercise of options Shares issued as purchase consideration for	18(b),19(b)	2,549,644		828,259	(578	,259)	-		-	-	250,000
Premium 5 acquisition	4,18(b)	180,156,643		30,626,629		-	-		-	-	30,626,629
Issuance of units, net of issuance costs Comprehensive income (loss)	18(b),19(a) 20	98,900,000		11,902,943	598	,392	(233,319))	(57,506,909)	- 54,696	12,501,335 (57,685,532)
Balance at October 31, 2021		786,128,570	\$	140,482,057	\$ 5,779	,474	, , ,			· · · · · · · · · · · · · · · · · · ·	\$ 55,220,439
Balance at October 31, 2021		786,128,570	\$	140,482,057	\$ 5,779	,474	\$ (197,307	') \$	(91,538,667)	\$ 694,882	\$ 55,220,439
Share-based payments - vesting of options	19(b)	-		-	389	,895	=		=	-	389,895
Share-based payments - issuance of shares Shares cancelled as consideration for debt	18(b)	7,109,090		355,455		-	-		-	-	355,455
assumed	18(b)	(933,333)		(126,000)	(14	,000)	-		-	-	(140,000)
Shares issued as contingent consideration											
payment for Premium 5 acquisition	16(d),18(b)	107,142,857		6,428,571		-	-		-	-	6,428,571
Shares issued as contingent consideration											
payment for Purefarma acquisition	16(a)(b), 18(b)	14,728,762		515,507		-	-		-	-	515,507
Shares issued for the acquisition of non-											
controlling interest in Heritage West	16(c),18(b),20	2,000,000		70,000		-	-		1,875,040	(1,595,039)	350,001
Warrants issued as consideration for loan											
amendment	15(b), 19(a)	-		-	747	,260	-		-	-	747,260
Exercise of warrants	18(b),19(a)	29,809		20,866		-	-		- (05.144.510)	-	20,866
Comprehensive income (loss)	20	-		-		-	306,710)	(25,144,640)	900,157	(23,937,773)
Balance at October 31, 2022		916,205,755	\$	147,746,456	\$ 6,902	,629	\$ 109,403	\$	(114,808,267)	\$ -	\$ 39,950,221

The accompanying notes are an integral part of these consolidated financial statements.

Consolidated Statements of Cash Flows Years Ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

	Notes	Years Ended Octob			tober 31,
			2022		2021
Operating Activities					
Net loss for the year		\$	(24,244,483)	\$	(57,452,213)
Items not affecting cash:			, , , ,		, , , ,
Amortization and depreciation	12,13		3,732,493		5,223,667
Depreciation in cost of sales	6,12,13		-		251,815
Loss on disposal of property, plant and equipment	13		2,849		-
Capitalized depreciation recognized in cost of sales	6		103,341		763,672
Inventory fair value increase recognized in cost of sales	6		(2.675.000)		583,087
Deferred income tax recovery Non-cash items included in interest and other income	21		(2,675,000)		(3,018,960)
Non-cash interest and finance expense	8,9 17		(97,574) 280,380		(5,000) 544,607
Shares issued for debt and services	18(b)		280,380		123,555
Share-based payments	18(b),19(b)		770,095		692,816
Loss on debt extinguishment, net of cash-settled transaction costs	15(b),19(a)		1,793,251		1,341,090
Share of loss from investment in associate	11		135,211		235,393
Unrealized loss (gain) on contingent consideration payable	16		(9,137,267)		3,514,865
Unrealized (gain) on derivative liabilities	17		(214,323)		(236,772)
Unrealized foreign exchange loss	11,25(c)(i)		1,289		20,244
Impairment of intangible assets and goodwill	12		21,215,000		36,337,826
Unrealized (gain) on other investments	10(ii)(iii)		(572,774)		-
Impairment of deposit	10(i)		106,104		
	2.1		(8,801,408)		(11,080,308)
Net changes in non-cash working capital, net of business combination	31		6,372,692		(9,045,884)
Cash Flows (Used in) Operating Activities			(2,428,716)		(20,126,192)
Investing Activities					
Acquisition of property, plant and equipment	13		(1,069,382)		(1,930,776)
Proceeds from disposal of property, plant and equipment	13		28,690		-
Issuance of notes receivable	9		(1,916,900)		-
Proceeds from sale of other investment	10(ii)		608,649		-
Maturity of convertible promissory note receivable	8		259,481		-
Cash acquired from business combination	4		-		1,281,341
Redemptions of short-term investments Cash Flows (Used in) Provided by Investing Activities	5		(2,089,462)		5,100,000 4,450,565
•			(_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Financing Activities	10/1		20.966		250,000
Proceeds from exercise of options and warrants Proceeds from issuance of units, net of cash-settled issuance costs	18(b) 18(b)		20,866		250,000 12,501,335
Principal payments on lease obligation	14		(80,106)		(49,879)
Principal payments on long-term debt, net of cash transaction costs	15		(5,321)		(4,677,029)
Proceeds from long-term debt, net of cash-settled transaction costs	15		4,939,009		9,151,618
Proceeds from derivative liability	17(b)		1,037,770		817,500
Cash payment for the acquisition of non-controlling interest	20		(50,000)		-
Cash Flows Provided by Financing Activities			5,862,218		17,993,545
Not In second to Cool Desire the Year			1 244 040		2 217 010
Net Increase in Cash During the Year Cash, Beginning of Year			1,344,040 3,763,577		2,317,918 1,445,659
Cash, End of Year		\$	5,107,617	\$	3,763,577
The accompanying notes are an integral part of these consolidated financial statements.					
Supplementary information					
Interest received		\$	3,836	\$	71,711
Interest paid	14,15	\$	-	\$	414,241
Shares and restricted shares issued for debt	18(b)	\$	_	\$	342,142
Shares issued for Premium 5 acquisition	16(d),18(b)	\$	6,428,571	\$	30,626,629
Shares issued for Purefarma acquisition	16(a)(b),18(b)	\$	515,507	\$	-
Other receivable settled as contingent consideration payment for Purefarma					
acquisition	16(a)(b)	\$	48,831	\$	-
Shares issued for the acquisition of non-controlling interest	18(b),20	\$	70,000	\$	-
Shares cancelled as consideration for debt assumed	18(b)	\$	140,000	\$	<u>-</u>
Non-cash share issuance costs	18(b),19(a)	\$	<u>-</u>	\$	598,392
Share-based payments in accrued liabilities for shares to be issued		\$	24,745	\$	-
Capitalized depreciation expense during the year	13	\$ \$	1,288,859	\$ \$	275,628 286,456
Right-of-use asset additions	15	Ф	-	\$	286,456

Notes to Consolidated Financial Statements For the Years Ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

Nature of business

Heritage Cannabis Holdings Corp. (the "Company") is a public company whose common shares trade on the Canadian Securities Exchange under the symbol "CANN". The Company was incorporated on October 25, 2007 in British Columbia, Canada, under the Business Corporations Act and commenced operations on November 1, 2007. On January 9, 2018, the Company changed its name to Heritage Cannabis Holdings Corp. The head office and principal address of the Company is Suite 600-77 Bloor Street West, Toronto, Ontario, Canada, M5S 1M2 and the registered office of the Company is located at Suite 1500-1055 West Georgia Street, Vancouver, British Columbia, Canada, V6E 4N7.

The Company is a vertically integrated cannabis business. In Canada, through its subsidiaries, Heritage Cannabis West Corporation ("Heritage West") and Heritage Cannabis East Corporation ("Heritage East"), the Company holds licenses under the Cannabis Act (Canada) and its relevant regulations. Heritage West, a holder of a cultivation, processing, medicinal and adult use, and cannabis oil sales licenses, as well as an industrial hemp license, operates out of a 15,500 square foot facility in Falkland, British Columbia. Heritage East, a holder of a cultivation, processing and medicinal and adult use sales license, as well as an industrial hemp license, operates out of a 122,000 square foot facility in Fort Erie, Ontario. Purefarma Solutions Inc. ("Purefarma"), a wholly-owned subsidiary, provides the Company with the experience and know-how necessary to manufacture, refine and formulate cannabis oils. CALYX Life Sciences Corp. ("CALYX"), a wholly-owned subsidiary, creates products and services aimed at providing an integrative approach to cannabinoid therapy for healthcare consumers and healthcare practitioners. Subsequent to October 31, 2022, Purefarma and CALYX amalgamated as disclosed in Note 32. On January 25, 2021, the Company acquired 100% of Premium 5 Ltd., a Canada-based recreational and medical cannabis company in high-quality full spectrum concentrates. In the United States, the Company operates under Opticann, Inc., a Colorado based oral and topical cannabinoid company.

1. Basis of presentation

(a) Going concern

Although the Company was awarded licenses and has invested resources into its business, the Company is not yet generating positive cash flows from operations and as such, it must rely, in part, on equity and debt financing to fund operations. To date, the Company's main source of funding has been the issuance of equity securities for cash through private placements to sophisticated investors, public offerings to institutional investors, and issuances of long-term debt.

These consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern. This assumes that the Company will operate for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. The Company incurred net loss of \$24,244,483 for the year ended October 31, 2022 (2021 - \$57,452,213), and had an accumulated deficit of \$114,808,267 as at October 31, 2022 (2021 - \$91,538,667). The Company's ability to arrange additional financing in the future depends, in part, on the prevailing capital market conditions. These factors indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern.

The consolidated financial statements do not give effect to adjustments that would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and liquidate its liabilities, contingent obligations and commitments other than in the normal course of business and at amounts different from those in these consolidated financial statements.

Notes to Consolidated Financial Statements For the Years Ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

1. Basis of presentation (continued)

(b) Statement of compliance

The consolidated financial statements have been prepared using accounting policies in compliance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations of the International Financial Reporting Interpretations Committee ("IFRIC") applicable to the preparation of these consolidated financial statements.

These consolidated financial statements were approved by the Board of Directors on February 23, 2023.

(c) Basis of measurement

These consolidated financial statements have been prepared on the going concern basis, under the historical cost convention except for investment in Stanley Park Digital Ltd. ("SPD"), investment in 1186366 B.C. Ltd., convertible promissory note receivable, notes receivable, acquisition-related contingent consideration payable, and derivative liabilities which are measured at fair value. These consolidated financial statements have been prepared on an accrual basis except for cash flow information.

(d) Functional and presentation currency

These consolidated financial statements are presented in Canadian dollars ("CDN") unless otherwise noted. The functional currency of Heritage US Holdings Corp., Heritage (US) Cali Corp., Heritage (US) Oregon Corp., Heritage (US) Colorado Corp., Opticann, Inc. and Endocanna Health, Inc. ("Endocanna") is the U.S. dollar ("USD"). The functional currency of the remaining entities is the Canadian dollar.

(e) Basis of consolidation

These consolidated financial statements include the accounts of the Company and its subsidiaries, with intercompany balances and transactions eliminated on consolidation. Subsidiaries are those entities over which the Company has control, which exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity and is exposed to the variable returns from its activities. As of October 31, 2022, subsidiaries over which the Company has control are listed below.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

1. Basis of presentation (continued)

(e) Basis of consolidation (continued)

		Jurisdiction of
Subsidiaries	Ownership Percentage	Incorporation
1005477 B.C. Ltd.	100%	British Columbia, Canada
333 Jarvis Realty Inc.	100%	Ontario, Canada
5450 Realty Inc.	100%	British Columbia, Canada
CALYX Life Sciences Corp. (Note 32)	100%	British Columbia, Canada
Heritage Cannabis East Corp.	100%	Ontario, Canada
(formerly CannaCure Corp.)		
Heritage Cannabis West Corp. (Note 20)	100%	British Columbia, Canada
(formerly Voyage Cannabis Corp.)		
Heritage Cannabis Exchange Corp.	100%	Ontario, Canada
Heritage (US) Cali Corp.	100%	California, United States
Heritage (US) Colorado Corp.	100%	Delaware, United States
Heritage US Holdings Corp.	100%	Delaware, United States
Heritage (US) Oregon Corp.	100%	Oregon, United States
Mainstrain Market Ltd. (Note 20)	100%	British Columbia, Canada
Opticann, Inc.	100%	Colorado, United States
Premium 5 Ltd.	100%	Alberta, Canada
Purefarma Solutions Inc. (Note 32)	100%	British Columbia, Canada

Certain subsidiaries are controlled, indirectly, through other subsidiaries.

(f) Estimates and critical judgements made by management

The preparation of these consolidated financial statements in conformity with IFRS requires management to make judgments and estimates that affect the reported amounts of assets and liabilities and disclosures of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The consolidated financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting adjustments based on future occurrences.

Revisions to accounting estimates are recognized in the period in which the estimate is revised and may affect both the period of revision and future periods. While management believes that the estimates are reasonable, actual results could differ materially from those estimates and may impact the future results of operations.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

1. Basis of presentation (continued)

- (f) Estimates and critical judgements made by management (continued)
 - (i) Share-based payment transactions

Certain equity-settled transactions are measured by reference to the fair value of the equity instruments granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This also requires determining the most appropriate inputs to the valuation model including the expected life of the share option or warrant, volatility and dividend yield.

(ii) Business combinations

In a business combination, the Company may acquire assets and assume certain liabilities of an acquired entity. Judgement is used in determining whether an acquisition is a business combination or an asset acquisition. Estimates are made as to the fair value of the identifiable assets acquired and the liabilities assumed on the acquisition date, as well as the fair value of consideration paid and contingent consideration payable. In certain circumstances, such as the valuation of property, plant and equipment, intangible assets and goodwill acquired, the Company may rely on independent third-party valuators. The determination of these fair values involves a variety of assumptions, include revenue growth rates, expected operating income, discount rates, and earnings multiples.

(iii) Estimated useful lives and depreciation of property, plant and equipment, right-of-use assets and intangible assets with finite lives

Depreciation and amortization of property, plant and equipment, right-of-use assets and intangible assets with finite lives are dependent upon estimates of useful lives and when the asset is available for use, which are determined through the exercise of judgment and are dependent upon estimates that take into account factors such as economic and market conditions, frequency of use, anticipated changes in laws and technological improvements.

(iv) Impairment of property, plant and equipment, right-of-use assets and intangible assets other than goodwill

The assessment of any impairment on property, plant and equipment, right-of-use assets and intangible assets other than goodwill is dependent upon estimates of recoverable amounts. As the recoverable amount is the higher of fair value less costs of disposal ("FVLCD") and value in use ("VIU"), management must consider factors such as economic and market conditions, estimated future cash flows, discount rates and asset-specific risks.

(v) Impairment of goodwill

The impairment test for cash generating units ("CGUs") to which goodwill is allocated is based on the higher of VIU and FVLCD of the CGU, determined in accordance with the expected cash flow approach. The calculation is based on assumptions including, but not limited to, the cash flow growth rate and the discount rate. See Note 12.

(vi) Determination of CGUs

Management is required to use judgement in determining which assets or group of assets make up appropriate CGUs for the level at which goodwill and intangible assets with indefinite lives are tested for impairment. A CGU is defined as the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

1. Basis of presentation (continued)

(f) Estimates and critical judgements made by management (continued)

(vii) Valuation of financial instruments

The Company makes estimates and assumptions relating to the fair value measurement and disclosure of its convertible promissory note receivable, notes receivable, private company investments, contingent consideration payable and derivative liabilities. The fair values are determined using a variety of valuation techniques. The inputs to these models are derived from observable market data where possible, but where observable market data are not available, management's judgment is required to establish fair values.

(viii) Control, joint control or significant influence

In determining the appropriate basis of accounting for the Company's interests in investees, judgment is applied regarding the degree to which the Company has the ability to control or exert significant influence over, directly or indirectly, the investees' financial and operating activities.

(ix) Income taxes and recoverability of potential deferred tax assets

Income taxes and tax exposures recognized in the consolidated financial statements reflect management's best estimates based on facts known at the reporting date. When the Company anticipates a future income tax payment based on its estimates, it recognizes a liability. The difference between the expected amount and the final tax outcome has an impact on current and deferred taxes when the Company becomes aware of this difference.

In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences.

(x) Inventory

Inventory is valued at the lower of cost and net realizable value. Determining net realizable value requires the Company to make assumptions about estimated selling prices in the ordinary course of business and the estimated variable costs to sell. Determining cost requires the Company to make estimates surrounding capacity and to allocate both direct and indirect costs on a systematic basis.

(xi) Expected credit losses on financial assets

Determining an allowance for expected credit losses ("ECLs") for all debt financial assets not held at fair value requires management to make assumptions about the historical patterns for the probability of default, the timing of collection and the amount of incurred credit losses. These assumptions are adjusted based on management's judgment about whether economic conditions and credit terms are such that actual losses may be higher or lower than what the historical patterns suggest.

(xii) Going concern

The assessment of the Company's ability to execute its strategy by funding future working capital requirements involves judgement. Management monitors future cash requirements to assess the Company's ability to meet these future funding requirements. Further information regarding going concern is outlined in Note 1(a).

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

1. Basis of presentation (continued)

(f) Estimates and critical judgements made by management (continued)

(xiii) Provisions

Provisions are recognized when the Company has a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows.

(xiv) Discount rates and lease terms used in application of IFRS 16, Leases

The determination of the Company's lease liabilities and right-of-use assets depends on certain assumptions, which include the selection of the discount rate. The discount rate is set by reference to the Company's incremental borrowing rate. Management determines the incremental borrowing rate for each leased asset by taking into account the Company's credit standing, the guarantee, the term and the value of the underlying leased asset, as well as the economic environment in which the leased asset is operated. Incremental borrowing rates can be changed due to macroeconomic changes in the environment. To determine the appropriate lease term, management considers all relevant facts and circumstances that create an economic incentive for the Company to exercise a renewal option or not to exercise a termination option. The periods covered by the renewal options are included in the lease term only if management is reasonably certain it will renew the lease. Changes in the assumptions used may have a significant effect on the consolidated financial statements.

2. Significant accounting policies

(a) Business combination

Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition date fair values of the assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interests issued by the Company in exchange for control of the acquiree. Acquisition related costs are generally recognized in profit or loss as incurred. At the acquisition date, the identifiable assets acquired and the liabilities assumed are recognized at their fair value.

Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition date amounts of identifiable assets acquired and liabilities assumed. If, after assessment, the net of the acquisition date amounts of identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognized immediately in profit or loss as a bargain purchase gain.

Non-controlling interests that are present ownership interests and entitle their holders to a proportionate share of the entity's net assets in the event of liquidation may be initially measured either at fair value or at the non-controlling interests' proportionate share of the recognized amounts of the acquiree's identifiable net assets. The choice of measurement basis is made on a transaction-by-transaction basis. Other types of non-controlling interests are measured at fair value or, when applicable, on the basis specified in another IFRS.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

3. Significant accounting policies (continued)

(a) Business combination (continued)

When the consideration transferred by the Company in a business combination includes assets or liabilities resulting from a contingent consideration arrangement, the contingent consideration is measured at its acquisition date fair value and included as part of the consideration transferred in a business combination. Changes in the fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with corresponding adjustments against goodwill. Measurement period adjustments are adjustments that arise from additional information obtained during the 'measurement period' (which cannot exceed one year from the acquisition date) about facts and circumstances that existed at the acquisition date.

The subsequent accounting for changes in the fair value of the contingent consideration that do not qualify as measurement period adjustments depends on how the contingent consideration is classified. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Other contingent consideration is remeasured to fair value at subsequent reporting dates with changes in fair value recognized in profit or loss.

When a business combination is achieved in stages, the Company's previously held equity interest in the acquiree is remeasured to its acquisition date fair value and the resulting gain or loss, if any, is recognized in profit or loss. Amounts arising from interests in the acquiree prior to the acquisition date that have previously been recognized in other comprehensive income are reclassified to profit or loss where such treatment would be appropriate if that interest were disposed of.

If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the Company reports provisional amounts for those items for which the accounting is incomplete. The provisional amounts are adjusted during the measurement period, not to exceed 12 months, or additional assets or liabilities may be recognized to reflect additional information obtained about facts and circumstances that existed at the acquisition date that, if known, would have affected the amounts recognized at that date.

(b) Cash and cash equivalents

Cash includes cash on hand and demand deposits. Cash equivalents comprises short-term, highly liquid investments that are readily convertible to known amounts of cash which are subject to an insignificant risk of change and have maturities of three months or less from the date of acquisition, held for the purpose of meeting short-term cash commitments rather than for investing or other purposes. The Company had no cash equivalents at the end of the reporting periods presented.

(c) Inventories

Inventories are initially valued at cost and subsequently at the lower of cost and net realizable value. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Cost is determined using the average cost basis.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

2. Significant accounting policies (continued)

(d) Intangible assets

Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over the assets' estimated useful lives.

Licenses 4 to 20 years
Intellectual property 10 years
Brands 3 to 10 years
Board relationships 10 years

Estimated useful lives and amortization methods are reviewed at the end of each reporting period, with the effect of any changes in estimates being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses.

Intangible assets acquired in a business combination and recognized separately from goodwill are initially recognized at their fair value at the acquisition date (which is thereafter regarded as their cost). Subsequent to initial recognition, intangible assets acquired in a business combination are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.

(e) Property, plant and equipment and right-of-use assets

Property, plant and equipment and right-of-use assets are carried at cost less accumulated depreciation and accumulated impairment losses. Depreciation is recognized on a straight-line basis over the assets' estimated useful lives.

Buildings and improvements 20 years
Equipment 10 years

Right-of-use assets Lesser of lease term or useful life

An asset's residual value, useful life and depreciation method are reviewed at the end of each reporting period and adjusted if appropriate. When parts of an item of plant, property and equipment have different useful lives, they are accounted for as separate items.

During their construction, property, plant and equipment are not subject to depreciation. When the asset is available for use, depreciation commences.

Gains and losses on the disposal of an item are determined by comparing the proceeds from disposal with the carrying amount of the item and recognized in profit or loss.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

2. Significant accounting policies (continued)

(f) Impairment of long-lived assets

Impairment tests on goodwill and intangible assets with indefinite useful lives are undertaken annually at the financial year-end and whenever there is an indication that these assets may be impaired. For other long-lived assets, the Company reviews their carrying amounts at the end of each reporting period to determine whether there is any indication that the carrying amount is not recoverable. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where the carrying value of an asset exceeds its recoverable amount, the asset is written down accordingly.

The recoverable amount is the higher of VIU and FVLCD. Fair value is determined as the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. In assessing value in use, the estimated future cash flows resulting from the asset's use and eventual disposition are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

When an individual asset does not generate independent cash flows, the Company estimates the recoverable amount of the CGU to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual CGUs, or otherwise they are allocated to the smallest group of CGUs for which a reasonable and consistent allocation basis can be identified.

(g) Financial instruments

All financial instruments are initially recorded at fair value at the time of acquisition. The Company aggregates its financial instruments in accordance with IFRS 9, Financial Instruments, into classes based on their nature and characteristics. Management determines the classification when the instruments are initially recognized, which is normally the date of the transaction. The Company's accounting policy for each class of financial instruments is as follows:

(i) Amortized cost

This category includes financial assets that are held within a business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the solely principal and interest ("SPPI") criterion, and financial liabilities which are not required, and for which the Company has not elected to subsequently record at fair value through profit or loss.

Financial instruments in this category are initially recognized at fair value plus directly attributable transaction costs. Subsequently, these instruments are measured at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial instrument and of allocating interest over the relevant period. The effective interest rate is the rate that discounts estimated future cash receipts through the expected life of the financial instrument, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. Financial assets are adjusted for any expected credit losses ("ECLs").

Financial assets in this category include cash, short-term investments, and accounts receivable. Financial liabilities in this category include accounts payable and accrued liabilities and long-term debt.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

2. Significant accounting policies (continued)

(g) Financial instruments (continued)

(ii) Fair value through profit or loss ("FVTPL")

This category includes derivative instruments and debt instruments whose cash flow characteristics fail the SPPI criterion or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell.

These financial instruments are initially recognized at fair value; all transaction costs are recognized immediately in profit or loss. Subsequently, these instruments are recognized at fair value at each reporting date. Any changes in fair value, and gains or losses upon disposition of the financial instruments are recognized in profit or loss.

Financial assets and liabilities in this category include convertible promissory note receivable, notes receivable, investments in 1186366 B.C. Ltd., investment in SPD, contingent consideration payable and derivative liabilities.

(iii) Fair value through other comprehensive income ("FVOCI")

This category only includes equity instruments, which the Company intends to hold for the foreseeable future and which the Company has irrevocably elected to so classify upon initial recognition or transition.

Equity instruments in this category are subsequently measured at fair value with changes recognized in other comprehensive income, with no recycling of gains or losses to profit or loss upon derecognition. Dividend income is recognized in earnings. Equity instruments at FVOCI are not subject to an impairment assessment under IFRS 9.

The Company did not have any financial instruments in this category as at October 31, 2022 and 2021.

(h) Impairment of financial assets at amortized cost

The Company recognizes a loss allowance for expected credit losses on cash, short-term investments and accounts receivable. The amount of expected credit losses is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial instrument. The Company recognizes lifetime ECLs for accounts receivable. The expected credit losses on these financial assets are estimated using a provision matrix based on the Company's historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the forecast direction of conditions at the reporting date, including time value of money where appropriate. For all other financial instruments, the Company recognizes the loss allowance for that financial instrument at an amount equal to 12-month ECLs. However, when there has been a significant increase in credit risk on these other financial instruments since initial recognition, lifetime ECLs are recognized. Lifetime ECLs represent the expected credit losses that will result from all possible default events over the expected life of a financial instrument. In contrast, 12-month ECLs represents the portion of lifetime ECL that is expected to result from default events on a financial instrument that are possible within 12 months after the reporting date.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

2. Significant accounting policies (continued)

(i) De-recognition of financial instruments

The Company de-recognizes a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and reward of ownership of the asset to another party. On de-recognition of a financial asset in its entirety, the difference between the asset's carrying amount and the sum of the consideration received and receivable is recognized in profit or loss.

The Company de-recognizes financial liabilities when, and only when, the Company's obligations are discharged, cancelled or have expired. The difference between the carrying amount of the financial liability de-recognized and the consideration paid and payable is recognized in profit or loss.

(j) Investments in associates

Significant influence is the power to participate in the financial and operating policy decisions of the associate without control or joint control over those policies. Significant influence is presumed to exist if the Company holds between 20% and 50% of the voting rights, unless evidence exists to the contrary. The Company has assessed that it has significant influence over Endocanna (Note 11). Associates in which the Company has significant influence are accounted for using the equity method. The Company's interest is initially recorded at cost, including transaction costs, and is subsequently adjusted for the Company's share of the associate's profit or loss and other comprehensive income, less any impairment in the value of individual investments, less any dividends received. Where the Company transacts with an associate, profits and losses are eliminated to the extent of the Company's interest in the associate. If the Company's share of losses equals or exceeds its interest in the associate, the Company does not recognize further losses, unless it has incurred obligations or made payments on behalf of the associate.

(k) Leases

The Company accounts for lease contracts in accordance with IFRS 16, Leases.

At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. In addition, the right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property, plant and equipment.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. The lease liability is subsequently measured at amortized cost using the effective interest method. The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

2. Significant accounting policies (continued)

(1) Income taxes

Income tax expense is comprised of current and deferred tax. Current and deferred income tax are recognized in the consolidated statements of operations and comprehensive loss except to the extent that they relate to a business combination or items recognized directly in equity or other comprehensive income, in which case the income tax is also recognized directly in equity or other comprehensive income. Current income taxes are the expected taxes payable on the taxable income for the year, using tax rates enacted, or substantively enacted, at the end of the reporting period, and any adjustments to taxes payable in respect of previous years.

Deferred tax assets and liabilities are recognized in respect of all qualifying temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined on a non-discounted basis using tax rates and laws that have been enacted or substantively enacted at the financial position date and are expected to apply when the deferred tax asset or liability is settled. Deferred tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the asset can be utilized.

At the end of each reporting period, the Company reassesses unrecognized deferred tax assets. The Company recognizes a previously unrecognized deferred tax asset to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset tax assets and liabilities and when the deferred tax balances relate to the same taxation authority. Deferred income tax assets and liabilities are presented as non-current.

(m) Share capital

Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Company's common shares, share options, restricted shares, restricted share units ("RSU") and certain warrants are classified as equity instruments.

(n) Share-based payments

Equity-settled share-based payments to directors, officers and employees are measured at the fair value of the equity instruments at the grant date and are recognized as an expense over the relevant vesting periods with a corresponding credit to contributed surplus.

Equity-settled share-based payments to non-employees are measured at the fair value of the goods or services received or the fair value of the equity instruments granted, if it is determined that the fair value of the goods or services received cannot be reliably measured. The fair value of equity-settled share-based payments to non-employees is recorded as an expense at the date the goods or services are received with a corresponding credit to contributed surplus.

The number of equity instruments expected to vest is reviewed and adjusted at the end of each reporting period such that the amount recognized for services received as consideration for the equity instruments granted shall be based on the number of equity instruments that eventually vest. After the vesting date, amounts recorded for expired instruments remain in contributed surplus.

In the case of stock options, proceeds received from stock option holders are recorded as an increase to share capital upon exercise and the related reserve balance in contributed surplus is transferred to share capital. In the case of RSUs, the related reserve balance in contributed surplus is transferred to share capital upon release of the underlying restrictions.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

2. Significant accounting policies (continued)

(o) Basic and diluted income (loss) per share

Basic income (loss) per share is computed by dividing the net income (loss) for the reporting period by the weighted average number of common shares outstanding for the relevant reporting period. Diluted income (loss) per common share is computed by dividing the net income (loss) applicable to common shares by the sum of the weighted average number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive instruments were converted.

(p) Share purchase warrants

The Company has adopted the residual value method with respect to the measurement of shares and warrants issued as private placement units. The residual value method first allocates value to the more easily measurable component based on fair value and then the residual value, if any, to the less easily measurable component. The fair value of the common shares issued in private placements is determined to be the more easily measurable component and they are valued at their fair value, as determined by the closing quoted bid price on the measurement date. The remainder, if any, is allocated to the attached warrants. Any fair value attributed to the warrants is recorded in contributed surplus.

(q) Revenue recognition

Revenue is recognized at the amount of the transaction price that is allocated to the performance obligation. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer.

Regarding the cannabis concentrate sales, the Company has three revenue streams: White label production, which includes bulk sales of crude oil, own branded products and tolling services.

White label production requires the Company to purchase dried cannabis either through long-term supply agreements or through spot purchases. The Company extracts, and depending on the requirements of the Licensed Producers ("LP"), may also purify, formulate and/or package the oil. The Company sells the cannabis concentrates to the LP customers at wholesale prices. Revenue from white label production is recognized when control of the product is transferred, that being when the product is delivered to the LP customer or in certain cases when delivery is deemed to have occurred. Deemed delivery occurs in situations where the white label contract has two deliverables — an initial sale and transfer of wholesale bulk crude oil, and, at the option of the customer, a subsequent sale of post-extraction refinement, formulation and packaging services. In this case, upon completion of the initial bulk oil extraction, the Company provides a formal notification to its customer of completion, readiness for delivery and timing of title transfer. At the request of the customer, the bulk oil may be held by the Company and undergo further refinement services, essentially taking on the characteristics of tolling services.

Sales of branded products include the sale of products to the various provincial boards. Revenue is recognized when control of the product is transferred, that being when the products are shipped to the various provincial boards as per purchase order and shipping document.

Tolling services work by LP partners supplying the Company with dried cannabis flower and the Company receives a tolling fee for producing cannabis concentrates. Revenue from tolling services is recognized when delivered or deemed delivered, in the case of a bill-and-hold arrangement, to the LP partner. Under tolling service agreements, the Company does not have any inventory risk as control over the inventory stays with the LP and the Company's consideration is in the form of a fee.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

2. Significant accounting policies (continued)

(q) Revenue recognition (continued)

(i) Remaining performance obligations

The Company's outstanding performance obligations in relation to customer contracts as at October 31, 2022 will be completed upon transfer of ownership (or deemed transfer) of extracts and as services are rendered. The Company's payment terms require payment without penalty to be made within 30 days after the customer accepts transfer of ownership or a notice of completion.

The outstanding performance obligations at year end require the Company to either (i) deliver crude cannabis extracts, and/or (ii) provide post extraction refinement, formulation, and packaging services. Revenue in the amount of \$681,548 (2021 - \$240,705 to be earned in the 2022 fiscal year) is expected to be earned in the 2023 fiscal year from contracts and orders in place as at October 31, 2022.

The contract to manufacture includes a standard limited warranty which holds the Company to certain assurances surrounding manufacturing practices and compliance with the Cannabis Act and its Regulations as well as other applicable laws.

(r) Foreign exchange translation

(i) Translation of foreign currency transactions

Transactions in foreign currencies are translated into the functional currency using the exchange rate prevailing at the date of the transaction. At each reporting date, foreign currency denominated monetary assets and liabilities are translated at year-end exchange rates. Exchange differences are recorded in profit or loss for the period.

(ii) Translation of foreign operations

The assets and liabilities of foreign operations are translated into Canadian dollars at year-end exchange rates. Income and expenses, and cash flows are translated into Canadian dollars using average exchange rates. Differences resulting from translating foreign operations are reported as translation differences in other comprehensive income and accumulated in equity. When a foreign operation is disposed of, the translation differences previously recognized in equity are reclassified to profit or loss.

(s) Government grants

Government grants are recognized when there is reasonable assurance that the Company will comply with the conditions attached to them and the government grants will be received. Grants are recognized as either income over the period(s) necessary to match them with the related costs or if related to a specific expense, as a reduction or contra to the expenses for which they are intended to compensate, on a systematic basis. Grants receivable for costs already incurred or for immediate financial support, with no future related costs, are recognized as income in the period in which the grant is receivable.

If a grant becomes repayable, it is treated as a change in estimate. Where the original grant related to income, the repayment would be applied first against any related unamortized deferred credit, and any excess would be expensed. Where the original grant related to an asset, the repayment would be treated as increasing the carrying amount of the asset or reducing the deferred income balance. The cumulative depreciation which would have been charged had the grant not been received would be charged as an expense.

The Company has elected to present the Canada Emergency Wage Subsidy ("CEWS"), a form of government grants, as a reduction of the corresponding payroll expenses. See Note 30.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

2. Significant accounting policies (continued)

(t) Provisions

Provisions are recognized for liabilities of uncertain timing or amount that have arisen as a result of past transactions, including legal or constructive obligations. The provision is measured at the best estimate of the expenditure required to settle the obligation at the reporting date.

3. New accounting standards and pronouncements

The following amendments were issued but not yet effective. The Company will adopt these amendments as of their effective dates. The Company is currently assessing the impacts of adoption.

(a) Amendments to IAS 1, Presentation of Financial Statements

IAS 1 was amended in January 2020 to address inconsistences with how entities apply the standard over classification of current and non-current liabilities. The amendment serves to address whether, in the statement of financial position, debt and other liabilities with an uncertain settlement should be classified as current or non-current. The amendment is effective for annual reporting periods beginning on or after January 1, 2023. Earlier adoption is permitted.

In February 2021, the IASB issued 'Disclosure of Accounting Policies' with amendments that are intended to help preparers in deciding which accounting policies to disclose in their financial statements. The amendments are effective for year ends beginning on or after January 1, 2023.

(b) Amendment to IAS 37, Provisions, Contingent Liabilities and Contingent Assets

IAS 37 was amended in May 2020 to clarify the costs a company should include as the cost of fulfilling a contract when assessing whether a contract is onerous. The amendment is effective for annual reporting periods beginning on or after January 1, 2022. Earlier adoption is permitted.

(c) Amendment to IAS 16, Property, Plant and Equipment

IAS 16 was amended in May 2020 to prohibit deducting from the cost of an item of property, plant and equipment any proceeds from selling items produced while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognizes the proceeds from selling such items, and the cost of producing those items, in profit or loss. The amendment is effective for annual reporting periods beginning on or after January 1, 2022. Earlier adoption is permitted.

(d) Amendment to IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors

In February 2021, the International Accounting Standards Board ("IASB") issued 'Definition of Accounting Estimates' to help entities distinguish between accounting policies and accounting estimates. The amendment is effective for annual reporting periods beginning on or after January 1, 2023. Earlier adoption is permitted.

(e) Amendments to IAS 12, Income Taxes

In May 2021, the IASB issued 'Deferred Tax Related to Assets and Liabilities Arising from a Single Transaction' that clarifies how entities account for deferred tax on transactions such as leases and decommissioning obligations. The amendments are effective for year ends beginning on or after January 1, 2023.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

3. New accounting standards and pronouncements (continued)

(f) Amendments to IFRS 10, Consolidated Financial Statements and IAS 28, Investments in Associates and Joint Ventures

IFRS 10 and IAS 28 were amended in September 2014 to address a conflict between the requirements of IAS 28 and IFRS 10 and clarify that in a transaction involving an associate or joint venture, the extent of gain or loss recognition depends on whether the assets sold or contributed constitute a business. The effective date of these amendments is yet to be determined, however early adoption is permitted.

(g) Amendments to IFRS 3, Business Combinations

The amendments introduce new exceptions to the recognition and measurement principles in IFRS 3 to ensure that the update in references to the revised conceptual framework does not change which assets and liabilities qualify for recognition in a business combination. An acquirer should apply the definition of a liability in IAS 37 – rather than the definition in the Conceptual Framework – to determine whether a present obligation exists at the acquisition date as a result of past events. For a levy in the scope of IFRIC 21, the acquirer should apply the criteria in IFRIC 21 to determine whether the obligating event that gives rise to a liability to pay the levy has occurred by the acquisition date. In addition, the amendments clarify that the acquirer should not recognize a contingent asset at the acquisition date. The amendments are effective for annual periods beginning on January 1, 2022.

4. Business combination

On January 25, 2021, the Company, through a wholly-owned subsidiary ("TransactionCo"), entered into a three-cornered amalgamation which resulted in the acquisition of all of the issued and outstanding shares of Premium 5 Ltd. ("Premium 5"), a Canada-based recreational and medical cannabis company in high-quality full spectrum concentrates. The amalgamation was completed on the same day, and the resulting amalgamated company changed its name to Premium 5 Ltd. The Company acquired Premium 5 as a strategic maneuver to leverage their distribution channels, brand recognition, and financial synergies.

Aggregate purchase consideration payable for all the outstanding and issued common shares in Premium 5 includes:

- (a) 150,000,000 common shares of the Company ("Heritage Common Shares") issued with a fair value of \$25,500,000, determined based on the closing share price of the Company at the acquisition date;
- (b) 30,156,643 Heritage Common Shares issued as additional compensation for Premium 5's excess working capital, with a fair value of \$5,126,629 determined based on the closing share price of the Company at the acquisition date;
- (c) Contingent performance payments payable in Heritage Common Shares, with a potential value of up to \$15,000,000, based on a fixed percentage of the excess net revenue over \$7,000,000 derived from certain products within the twelve months following the acquisition date ("First Performance Milestone"). The fair value of such contingent performance payments was determined as \$10,824,000, using the Black-Scholes model with the following inputs, assumptions and result; and
- (d) Contingent performance payment in the amount of \$5,000,000, payable in Heritage Common Shares, upon the Company's ability to achieve certain average gross margin target across all recreational products within the second twelve months following the acquisition date ("Second Performance Milestone"). The fair value of such contingent performance payment was determined as \$681,000, using the Black-Scholes model with the following inputs, assumptions and result.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

4. Business combination (continued)

	Performance
At January 25, 2021, the acquisition date	Milestone 1
Option type	Vanilla
Net revenue	\$23,072,960
Exercise price	\$7,000,000 - \$17,000,000
Time period (years)	1.00
Volatility	70%
Dividend yield	0.00%
Risk-free interest rate	0.10%
Calculated fair value of earnout	\$10,824,000
	Performance
At January 25, 2021, the acquisition date	Performance Milestone 2
At January 25, 2021, the acquisition date Option type	
- · · · · · · · · · · · · · · · · · · ·	Milestone 2
Option type	Milestone 2 Cash-or-nothing
Option type Gross margin	Milestone 2 Cash-or-nothing \$7,191,479
Option type Gross margin Cash payment	Milestone 2 Cash-or-nothing \$7,191,479 \$5,000,000
Option type Gross margin Cash payment Exercise price	Milestone 2 Cash-or-nothing \$7,191,479 \$5,000,000 \$10,487,325
Option type Gross margin Cash payment Exercise price Time period (years)	Milestone 2 Cash-or-nothing \$7,191,479 \$5,000,000 \$10,487,325 2.00
Option type Gross margin Cash payment Exercise price Time period (years) Volatility	Milestone 2 Cash-or-nothing \$7,191,479 \$5,000,000 \$10,487,325 2.00 125%

Management determined that the assets and processes comprised a business and therefore accounted for the transaction as a business combination using the acquisition method of accounting. The following table summarizes the fair value of the consideration transferred and the major classes of assets acquired and liabilities assumed at the acquisition date.

Total consideration paid					
180,156,643 Heritage Common Shares	\$	30,626,629			
Contingent performance payments (Note 16(d))	11,505,				
		42,131,629			
Fair value of identifiable net assets acquired					
Cash		1,281,341			
Accounts receivable		282,402			
Sales tax recoverable		102,379			
Inventories		3,910,371			
Prepaid expenses and deposits		18,757			
Advances to the Company		369,630			
Property, plant and equipment (Note 13)		726,041			
Brand (Note 12)		8,918,000			
Board relationships (Note 12)		1,034,000			
Accounts payable and accrued liabilities		(1,042,885)			
Lease liability (Note 14)		(546,344)			
Net assets, excluding deferred taxes		15,053,692			
Purchased goodwill		27,077,937			
Deferred tax liability (Note 21)		2,288,960			
Goodwill recognized (Note 12)	\$	29,366,897			

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

4. Business combination (continued)

Goodwill represents expected synergies, future income and growth potential, and other intangibles that do not qualify for separate recognition. None of the goodwill arising on this acquisition is expected to be deductible for tax purposes.

The fair value of intangible assets acquired has been determined using valuation techniques that require estimation of future earnings, future net cash flows, and discount rates. Changes in estimates and assumptions used could have a material impact on the amount of goodwill recorded and the amount of depreciation and amortization expense recognized in earnings for depreciable assets in future periods.

Since January 25, 2021, the acquisition date, Premium 5 commenced sales of its products through Heritage West and Heritage East, the cannabis license holders and wholly-owned subsidiaries of the Company. As such, management determined that it would be impracticable to determine the amount of trade revenues and profit or loss Premium 5 would have generated if the acquisition had been completed on November 1, 2020.

5. Short-term investments

As at October 31, 2022, short-term investments consisted of \$950,000 (2021 - \$950,000) in guaranteed investment certificates maintained with a Canadian chartered bank. The carrying value of these short-term investments approximates their fair value as at October 31, 2022 due to the short term to maturity. Of the total balance, \$50,000 is restricted and held as security against the Company's corporate credit card (2021 - \$50,000).

6. Inventories

	Oc	As at etober 31, 2022	Octo	As at ber 31, 2021
Supplies and packaging materials	\$	3,795,521	\$	3,032,189
Dried cannabis and hemp		1,356,397		1,615,938
Manufacturing work in progress		2,925,024		3,250,178
Finished goods		8,711,667		8,101,748
Other		-		124,188
	\$	16,788,609	\$	16,124,241

During the year ended October 31, 2022, inventories expensed to cost of sales was \$21,599,867 (2021 - \$9,827,525). As at October 31, 2022, \$1,288,859 (2021 - \$103,341) of capitalized depreciation remained in inventories.

7. Prepaid expenses and deposits

	Oc	As at October 31, 2022		
Inventory deposits	\$	1,115,500	\$	1,913,665
Prepaid insurance and consulting		46,071		65,577
Equipment deposits		309,929		40,971
Marketing		130,023		65,145
Other prepaid expenses		412,454		262,382
	\$	2,013,977	\$	2,347,740

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

8. Convertible promissory note receivable

In December 2019, the Company negotiated a promissory note from Empower Healthcare Assets Inc. ("Empower Health") for \$250,000, bearing interest at 2% per annum on the outstanding principal. The promissory note was due on demand and matured on December 31, 2021. The promissory note was guaranteed by Empower Health and Empower Clinics Inc. ("Empower Clinics"), an affiliated company of Empower Health. At the Company's option, the promissory note was convertible into the common shares of Empower Clinics based on the value of the common shares at the closing price the day before the conversion, or into the equity interest in the joint venture to be formed between the Company and Empower Health.

The convertible promissory note receivable was classified and measured at FVTPL. As at October 31, 2021, the convertible promissory note receivable had a fair value of \$259,481. As at October 31, 2022, the convertible promissory note receivable was fully repaid in cash.

9. Notes receivable

	U	e Cannabis ngs Corp. (a)	Orego	ge (US) n Corp. o)	То	tal
Balance as at October 31, 2021	\$	-	\$	-	\$	-
Advances		1,613,877		299,954		1,913,831
Interest income		97,574		3,069		100,643
Balance as at October 31, 2022		1,711,451		303,023		2,014,474
Less: current portion		(256,718)		(45,453)		(302,171)
Long-term portion	\$	1,454,733	\$	257,570	\$	1,712,303

(a) Heritage Cannabis Holdings Corp., the parent company

On May 3, 2021, the Company entered into an agreement, pursuant to which the Company agreed to provide an aggregate principal amount of up to \$1,000,000 USD ("Operating Loan") plus possible additional advances, if necessary. The Operating Loan bears an interest rate of 10% per annum and is payable over five years. Monthly payments are determined based on the gross margin collected and are due to begin once sales activities commence. As at October 31, 2022, the Company has disbursed \$1,613,877 CDN (equivalent to \$1,182,488 USD) in total.

(b) Heritage (US) Oregon Corp.

On September 9, 2021, Heritage (US) Oregon Corp. entered into an equipment purchase and service agreement with another company, with the same terms as those of the Missouri Agreement. As at October 31, 2022, the Company has disbursed \$299,954 CDN (equivalent to \$219,776 USD) in total.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

9. Notes receivable (continued)

The notes receivable are classified and measured at FVTPL. The Company applied a probability-weighted average valuation methodology, resulting in the notes receivable being valued at the present value of future payments discounted at the market rate of interest of 10%. No unrealized gain or loss was recognized as a result of changes in fair value of the notes receivable during the year ended October 31, 2022.

All the borrowers expect to commence sales imminently with monthly repayments starting in February 2023. Future undiscounted principal payments for the notes receivable, excluding variable service fees which are excluded from notes receivable, are as follows:

	<	1 year	2-5 years	>	5 years
Contractual cash flows	\$	287,075	\$ 1,531,065	\$	95,691

10. Other investments and deposits

		As at	As at		
	Octo	ber 31, 2022	Octob	er 31, 2021	
Refundable deposit for development costs (i)	\$	-	\$	106,104	
Investment in SPD (ii)		-		-	
Investment in 118366 B.C. Ltd (iii)		-		35,875	
Long-term deposits (iv)		799,812		296,699	
	\$	799,812	\$	438,678	

- (i) On February 16, 2018, Heritage East entered into an agreement with its municipality to conduct land development where its production facility is located. As part of this agreement, Heritage East deposited with the municipality a \$106,104 refundable letter of credit to guarantee the completion of these land development costs. As at October 31, 2022, management determined that the project was no longer viable and therefore wrote off the deposit in full.
- (ii) On April 30, 2020, the Company acquired 18% interest in SPD for total consideration of \$340,000. As at October 31, 2021, management determined the fair value of the investment in SPD as \$nil, given the investment was not in line with the Company's core business and therefore provided negligible value to the Company. On March 30, 2022, the Company sold its interest in SPD for total cash proceeds of \$608,649. Immediately preceding such sale, the investment was revalued to \$608,649, with the full amount recognized as an unrealized gain in profit or loss.
- (iii) On June 15, 2020, the Company received 76,923 common shares of 118366 B.C. Ltd. at a price of \$0.61 per share as settlement of \$46,914 accounts receivable for storage and other services provided. As a result, the Company acquired 5% interest in 118366 B.C. Ltd. As at October 31, 2022, the fair value of the investment was determined to be \$nil (2021 \$35,875) based on management's best estimates, with an unrealized loss of \$35,875 recognized in profit or loss.
- (iv) As at October 31, 2022, the long-term deposits were comprised of an excise duty deposit of \$710,000 (2021 \$215,000) and security deposits of \$89,812 (2021 \$81,699).

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

11. Investment in associate

On July 26, 2019, the Company acquired a 30% strategic interest in Endocanna, a company based in California, U.S.A. that develops saliva collection kits used in identifying genetic variants to facilitate cannabinoid formulation and dosing decisions.

A reconciliation of the carrying amount of the investment is detailed below:

Balance as at October 31, 2020	\$ 3,515,379
Share of net loss	(235,393)
Foreign currency translation	(235,804)
Balance as at October 31, 2021	\$ 3,044,182
Share of net loss	(135,211)
Foreign currency translation	305,422
Balance as at October 31, 2022	\$ 3,214,393

The following table summarized, in aggregate, the financial information of Endocanna in USD:

	As at	As at
	October 31, 2022	October 31, 2021
Cash and cash equivalents	\$ 10,509	\$ 72,529
Other current assets	187,060	241,766
Non-current assets	16,516	205,840
Current liabilities	186,456	347,010
Non-current liabilities	195,000	-
	For the year ended	For the year ended
	October 31, 2022	October 31, 2021
Revenue	\$ 284,676	\$ 152,250
Depreciation and amortization expense	216,110	216,844
Loss from continuing operations	349,026	619,275
Total comprehensive loss	349,026	619,275

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

12. Intangible assets and goodwill

		Licenses	Rel	Board ationships		Intellectual property	Brands	Goodwill (i)	Total
Cost		210011505				property	2141145	(1)	
As at October 31, 2021 Deduction as a result of fully	\$	29,208,072	\$	1,034,000	\$	7,250,000	\$ 9,530,500	\$ 4,858,330	\$ 51,880,902
impaired license Impairment		(971,073) (10,488,595)		- (385,399)		(2,152,103)	(3,330,573)	(4,858,330)	(971,073) (21,215,000)
Aa at October 31, 2022	\$	17,748,404	\$	648,601	\$	5,097,897	\$ 6,199,927	\$ -	\$ 29,694,829
Accumulated amortization									
As at October 31, 2021 Deduction as a result of fully impaired license	\$	4,621,026 (971,073)	\$	79,037 -	\$	1,769,794	\$ 1,157,766 -	\$ - -	\$ 7,627,623 (971,073)
Additions		1,411,849		103,400		725,000	1,013,629		3,253,878
As at October 31, 2022	\$	5,061,802	\$	182,437	\$	2,494,794	\$ 2,171,395	\$ -	\$ 9,910,428
Net book value as at October 31, 2022	\$	12,686,602	\$	466,164	\$	2,603,103	\$ 4,028,532	\$ -	\$ 19,784,401
]	Licenses		Board ationships]	Intellectual property	Brands	Goodwill (i)	Total
Cost									
As at October 31, 2020 Acquisition from business	\$	31,863,658	\$	-		\$ 7,250,000	\$ 612,500	\$ 9,191,433	\$ 48,917,591
Combination (Note 4) Foreign currency translation		(17,760)	1	1,034,000		-	8,918,000	29,366,897	39,318,897 (17,760)
Impairment		(2,637,826)		-		-	-	(33,700,000)	(36,337,826)
As at October 31, 2021	\$	29,208,072	\$	1,034,000		\$ 7,250,000	\$ 9,530,500	\$ 4,858,330	\$ 51,880,902
Accumulated amortization									
As at October 31, 2020 Additions	\$	2,302,511 2,318,515	\$	- 79,037	\$	1,044,794 725,000	\$ 271,922 885,844	\$ - -	\$ 3,619,227 4,008,396
As at October 31, 2021	\$	4,621,026	\$	79,037	\$	1,769,794	\$ 1,157,766	\$ -	\$ 7,627,623
Net book value as at October 31, 2021	\$	24,587,046	\$	954.963	\$	5,480,206	\$ 8.372.734	\$ 4.858.330	\$ 44.253,279

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

12. Intangible assets and goodwill (continued)

The details of individually material intangible assets are as follows:

	Carrying			
	As at		As at	Remaining
Description	October 31, 2022	О	October 31, 2021	Amortization Period
Heritage East cultivation, processing and sales licenses	\$ 10,467,574	\$	20,280,098	Approximately 16 years
Purefarma intellectual property	2,603,103		5,480,206	Approximately 6 years
Premium 5 board relationships	466,163	;	954,963	Approximately 8 years
Premium 5 brand	4,020,549)	8,236,323	Approximately 8 years
Heritage West processing and sales licenses	2,219,028	3	4,306,948	Approximately 16 years

(i) Below is a reconciliation of changes in the goodwill balance for the years ended October 31, 2022 and 2021:

	Purefarma	F	Heritage East	I	Ieritage West	F	Premium 5	Total	
As at October 31, 2020	\$ 2,711,016	\$	5,622,278	\$	858,139	\$	-	\$ 9,191,4	33
Acquired through business									
combination (Note 4)	-		-		-		29,366,897	29,366,89	97
Impairment	(2,369,429)		(4,913,874)		(750,014)		(25,666,683)	(33,700,0	(00)
As at October 31, 2021	\$ 341,587	\$	708,404	\$	108,125	\$	3,700,214	\$ 4,858,3	30
Impairment	(341,587)		(708,404)		(108,125)		(3,700,214)	(4,858,33	30)
As at October 31, 2022	\$ -	\$	-	\$	-	\$	-	\$	

As at October 31, 2022 and October 31, 2021, the full goodwill balance was allocated to the Canadian extraction CGU. The Company has assessed that there is a single cash generating unit. The Company assesses whether there are events or changes in circumstances that would more likely than not reduce the fair value of its CGU to below its carrying value and, therefore, require goodwill to be tested for impairment at the end of each reporting period.

As at October 31, 2022, the Company performed its annual impairment test on the goodwill based on the higher of VIU and FVLCD of the CGU, determined in accordance with the expected cash flow approach, a level 3 valuation technique. The recoverable amount was determined to be the FVLCD, in the amount of \$44,340,000. The key assumptions used in the calculation of the recoverable amount relate to five-year future cash flows, weighted average cost of capital, and five-year average growth rate. These key assumptions were based on historical data from internal sources as well as industry and market trends. The discount rate used was 18.2% (2021 - 12.5%) representing the weighted average cost of capital (after-tax) determined based on mid-year discounting, and the five-year average growth rate in gross revenue was estimated as 24% (2021 - 36.2%).

As the recoverable amount was below the carrying value by \$21,125,000 as at October 31, 2022, an impairment loss of \$4,858,330 (2021 - \$33,700,000) was recognized and allocated to goodwill, with the remaining allocated to other intangible assets based on their relative carrying amounts. Management has determined that the impairment was primarily due to shifting market dynamics.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

13. Property, plant and equipment

	Equipment		Buildings and improvements			Land	Total	
Cost								
At October 31, 2021	\$	8,733,798	\$	14,763,772	\$	930,157	\$ 24,427,727	
Additions		867,989		201,393		-	1,069,382	
Disposals		(38,088)		-	_	<u>-</u>	 (38,088)	
At October 31, 2022	\$	9,563,699	\$	14,965,165	\$	930,157	\$ 25,459,021	
Accumulated depreciation								
At October 31, 2021	\$	1,888,354	\$	1,769,407	\$	-	\$ 3,657,761	
Additions		955,297		812,177		-	1,767,474	
Disposals		(6,549)		-		-	(6,549)	
At October 31, 2022	\$	2,837,102	\$	2,581,584	\$	-	\$ 5,418,686	
Net book value at October 31, 2022	\$	6,726,597	\$	12,383,581	\$	930,157	\$ 20,040,335	
	E	quipment		nildings and provements		Land	Total	
Cost								
At October 31, 2020	\$	6,971,560	\$	13,636,149	\$	930,157	\$ 21,537,866	
Acquisitions from business combination (Note 4)		136,761		589,280		-	726,041	
Additions		1,625,477		591,755		-	2,217,232	
Deduction as a result of								
terminated lease		-		(53,412)		-	(53,412)	
At October 31, 2021	\$	8,733,798	\$	14,763,772	\$	930,157	\$ 24,427,727	
Accumulated depreciation								
At October 31, 2020	\$	935,348	\$	1,033,112	\$	-	\$ 1,968,460	
Additions		953,006		789,707		-	1,742,713	
Deduction as a result of								
terminated lease		-		(53,412)		-	(53,412)	
At October 31, 2021	\$	1,888,354	\$	1,769,407	\$	-	\$ 3,657,761	
Net book value at								
October 31, 2021	\$	6,845,444	\$	12,994,365	\$	930,157	\$ 20,769,966	

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

13. Property, plant and equipment (continued)

During the year ended October 31, 2022, the Company disposed of equipment, with a recognition of loss on disposal of \$2,489 in profit or loss

Below is a reconciliation of changes in the right-of-use assets, which are included in the buildings and improvements balance based on the nature of the underlying assets:

	Right-o	Right-of-use assets				
Cost						
As at October 31, 2020	\$	53,412				
Additions (Note 14)		286,456				
Acquisitions from business combination (Note 4)		546,344				
Deduction as a result of terminated lease		(53,412)				
As at October 31, 2021	\$	832,800				
Accumulated depreciation						
As at October 31, 2020	\$	29,134				
Additions		102,116				
Deduction as a result of terminated lease		(53,412)				
As at October 31, 2021	\$	77,838				
Net book value as at October 31, 2021	\$	754,962				
	Right-	of-use assets				
Cost						
As at October 31, 2021	\$	832,800				
As at October 31, 2022	\$	832,800				
Accumulated depreciation						
As at October 31, 2021	\$	77,838				
Additions		110,593				
As at October 31, 2022	\$	188,431				
Net book value as at October 31, 2022	\$	644,369				

As at October 31, 2022 and October 31, 2021, all of the Company's property, plant and equipment was domiciled in Canada.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

14. Lease liabilities

In January 2021, as part of the Premium 5 acquisition, the Company acquired an office lease, with an escalating monthly lease payment of \$7,123 to \$7,700 until April 22, 2031. In March 2021, the Company entered into another lease for office space with an escalating monthly lease payment of \$5,811 to \$6,423 until April 30, 2026, the end of the initial term, with a subsequent renewal through April 30, 2031. The Company applied a discount rate of 10% in the calculation of lease liabilities. The Company did not enter into any new leases which would require a recognition of right-of-use assets and lease liabilities during the year ended October 31, 2022.

The following is a continuity of lease liabilities:

		As at	As at		
	Oct	ober 31, 2022	Octo	per 31, 2021	
Beginning balance	\$	809,103	\$	26,182	
Acquired through business combination (Note 4)		-		546,344	
Additions		-		286,456	
Interest expense		76,097		62,235	
Lease payments		(156,203)		(112,114)	
Ending balance	\$	728,997	\$	809,103	
Less: current portion		(89,591)		(79,359)	
Long-term portion	\$	639,406	\$	729,744	

Future undiscounted lease payments for these leases, excluding certain operating expenses such as common area maintenance fees which are excluded from lease liabilities, are as follows:

	<1 year	2-	5 years	> 5 years
Contractual cash flows	\$ 157,953	\$	541,857	\$ 315,700

During the year ended October 31, 2022, the Company has recognized rent expenses of \$195,402 in profit or loss in relation to the short-term leases, low-value leases and variable lease payments which were excluded from the measurement of lease liabilities (2021 - \$94,757).

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

15. Long-term debt

	Octo	As at ber 31, 2022	As at October 31, 2021			
(a) Term loan - non-interest bearing, principal-only payments of \$585 per month, 6-year term, maturing on January 18, 2025	\$	14,098	\$	19,419		
(b) Term loan – comprised of four credit facilities for up to \$19,760,000, with the facilities bearing variable interest disclosed in Note 15(b). The loan is monthly interest-only payments, 26-				ŕ		
month term, maturing on November 30, 2024.		16,807,261		10,822,261		
	\$	16,821,359	\$	10,841,680		
Less: current portion		(5,878)		(5,321)		
Long-term portion	\$	16,815,481	\$	10,836,359		

- (a) The effective interest at a rate of 10% per annum has been imputed on the term loan, determined based on the Company's incremental cost of borrowing at the time of initial recognition. As at October 31, 2022, the face value of the term loan was \$15,802 (as at October 31, 2021 \$22,825). The term loan was secured by an equipment with a carrying value of \$25,087 as at October 31, 2021. During the year ended October 31, 2022, the Company disposed of the underlying equipment. Consequently, the term loan became unsecured as at October 31, 2022.
- (b) On March 31, 2021, the Company, along with its subsidiaries Heritage East, 333 Jarvis Realty Inc., Heritage West and 5450 Realty Inc., (together the "Borrowers") entered into an 18-month loan agreement for \$7,000,000. The effective interest rate implicit in the term loan is 10%.

The term loan is secured by the following:

- (i) A promissory note in the amount of \$7,000,000;
- (ii) mortgages and assignments of rents over certain properties owned by the Company;
- (iii) an environmental indemnity agreement;
- (iv) an encumbrance and charge of all of the Borrowers' right, title and interest in the Borrowers' present and future personal property and assets by way of a general security agreement;
- (v) an assignment of proceeds from the Borrowers' sales;
- (vi) assignments and postponements of creditors' claims from creditors of the Borrowers;
- (vii) joint and several unlimited guarantees inclusive of assignments and postponements of creditors' claims from each of the guarantors, including five of the Company's remaining subsidiaries (together the "Guarantors");
- (viii) general security agreements from the Borrowers and Guarantors inclusive of serial specific registration on certain assets;
- (ix) a pledge by the Company, each of its subsidiaries and all the investees in which the Company holds interests;
- (x) an assignment of material contracts and insurance agreements granted by the Company and each guarantor; and
- (xi) solicitors' opinions for Borrowers.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

15. Long-term debt (continued)

On October 6, 2021, the Company amended the loan agreement (the "First Amendment") by establishing three credit facilities for a maximum amount of \$14,775,000 as follows:

- (i) Facility 1: the initial loan is increased from \$7,000,000 to \$7,175,000, with the increase of \$175,000 to be used by the Company to pay to the lender an extension fee of \$175,000 to extend the due date to February 1, 2023;
- (ii) Facility 2: an additional loan of \$2,600,000 will be advanced at the Royal Bank of Canada prime rate plus 1.25% per annum;
- (iii) Facility 3: a revolving line of credit up to maximum of \$5,000,000 shall be established at an interest rate of 18% per annum.

As part of the First Amendment, the Company also issued 10,000,000 warrants to the lender. Each warrant is exercisable into one Heritage Common Share at an exercise price of \$0.25 per share and has a term of 24 months expiring on October 8, 2023. See Note 19(a). These warrants were considered exchangeable into a fixed number of Heritage Common Shares, and thus were classified as equity.

Based on management's assessment, the modification of the loan resulted in a substantial change in the carrying amount of the loan, and therefore was accounted for as an extinguishment of the original loan and a recognition of the new loan. The Company initially valued the Loan at its fair value at the modification date, using the effective interest rate of 5.08% implicit in the Loan, with \$nil residual value to the warrants. The difference between the fair value of the Loan and the original loan, as well as the transaction costs incurred as part of modification in the amount of \$1,361,338 were recognized in profit or loss at the modification date.

On September 29, 2022, the Company amended the loan agreement for the 2nd time (the "Second Amendment") by establishing four credit facilities for a maximum amount of \$19,760,000 (collectively the "Loan") as follows:

- (i) Facility 1: \$7,175,000. The interest rate is a) the Royal Bank of Canada rate minus 1.75% from October 1, 2022 to July 31, 2023; b) the Royal Bank of Canada rate plus 10% from August 1, 2023 to November 30, 2024, but in no case less than 14% or greater than 18% per annum;
- (ii) Facility 2: \$2,600,000. The interest rate is a) the Royal Bank of Canada rate minus 1.75% from October 1, 2022 to July 31, 2023; b) the Royal Bank of Canada rate plus 10% from August 1, 2023 to November 30, 2024, but in no case less than 14% or greater than 18% per annum;
- (iii) Facility 3: A revolving line of credit up to a maximum of \$5,000,000. The interest rate is a) 15% per annum from October 1, 2022 to July 31, 2023; b) the greater of the Royal Bank of Canada rate plus 10% and 15% per annum from August 1, 2023 to November 30, 2024;
- (iv) Facility 4: an additional loan of \$4,985,000, inclusive of the loan amendment fee of \$985,000. The interest rate is a) the Royal Bank of Canada rate minus 1.75% from October 1, 2022 to July 31, 2023; b) the Royal Bank of Canada rate plus 10% from August 1, 2023 to November 30, 2024, but in no case less than 14% or greater than 18% per annum.

The Loan due date was extended to November 30, 2024, with an option to extend to November 30, 2025. If the Company exercises its extension option, all facilities will bear an interest rate at the maximum of either the Royal Bank of Canada prime rate plus 10% or 15% per annum during the one-year extension period. As at October 31, 2022, the Company has received a total of \$16,807,261 in principal, with the remaining line of credit \$2,952,739 available for advance.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

15. Long-term debt (continued)

As part of the Second Amendment, the Company extended the expiry date of the initial 10,000,000 warrants, which are exercisable into one Heritage Common Share at an exercise price of \$0.25 per share, from October 8, 2023 to February 28, 2025. The Company also issued another 50,000,000 warrants which are exercisable into one Heritage Common Share at an exercise price of \$0.10 per share expiring on February 28, 2025. Provided that the Company exercises its option to extend the Loan by an extra 12 months, the expiry date of all 60,000,000 warrants shall be extended to February 28, 2026. The amendment to the initial 10,000,000 warrants was accounted for as a cancellation of old warrants and an issuance of new warrants. At the modification date, both the modified and newly issued warrants were considered exchangeable into a fixed number of Heritage Common Shares, and thus were classified as equity.

Based on management's assessment, the Second Amendment of the Loan resulted in a substantial change in the carrying amount of the Loan, and therefore was accounted for as an extinguishment of the original loan and a recognition of the new loan. The Company initially valued the Loan at its fair value at the modification date, using the effective interest rate of 12% per annum implicit in the Loan. The difference between the fair value of consideration and the original loan, as well as the transaction costs incurred as part of the Second Amendment in the amount of \$1,793,251 (2021 - \$1,361,338), including all 60,000,000 warrants issued as transaction costs with a value of \$747,260 (Note 19(a)), were recognized in profit or loss at the modification date.

Below is a reconciliation of changes in the carrying amount of the term loan:

Proceeds from term loan	\$ 7,000,000
Transaction costs, cash-settled	(1,111,433)
Transaction costs, equity-settled	(28,000)
Balance at inception of the term loan	5,860,567
Interest expense	129,500
Interest payments	(129,500)
Accretion	357,553
Balance as at October 6, 2021, the modification date	\$ 6,218,120
Advances, net of cash-settled transaction costs	3,263,051
Loss on debt extinguishment from changes in carrying amount and	, ,
transaction costs withheld by lender as a result of modification (i)	1,341,090
Interest expense	31,556
Interest payments	(31,556)
Balance as at October 31, 2021	\$ 10,822,261
Advances, net of cash-settled transaction costs	1,000,000
Interest expense	741,420
Interest payments	(741,420)
Balance as at September 29, 2022, the modification date	\$ 11,822,261
Advances, net of cash-settled transaction costs	3,939,009
Loss on debt extinguishment from changes in carrying amount and	-,,-,,,-,,
cash-settled transaction costs as a result of modification (i)	1,045,991
Interest expense	47,093
Interest payments	(47,093)
Balance as at October 31, 2022	\$ 16,807,261

⁽i) In addition, the fair value of \$747,260 of the 60,000,000 warrants, issued as non-cash transaction costs in connection with the modification, was recognized as loss on debt extinguishment.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

16. Contingent Consideration Payable

Balance as at October 31, 2020	\$	1,510,311
Issued in Premium 5 acquisition (Note 4)		11,505,000
Loss from remeasurement		3,514,865
Balance as at October 31, 2021	\$	16,530,176
Payment made through issuance of common shares on contingent		
consideration issued in Premium 5 acquisition (Note 4)		(6,428,571)
Payment made through issuance of common shares on contingent		
consideration issued in Purefarma acquisition and settlement of other		
receivable (Note 16(b) and Note 18(b))		(564,338)
Settlement of contingent consideration payable issued in Heritage West		
acquisition as a result of purchase of non-controlling interest in Herita	ge	
West (Note 20)		(400,000)
(Gain) from remeasurement		(9,137,267)
Balance as at October 31, 2022	\$	

(a) Contingent consideration issued in Purefarma acquisition, equity-settled

On December 14, 2018, the Company acquired all the issued and outstanding shares of Purefarma Solutions Inc. ("Purefarma"). In connection with the acquisition, the Company was required to make certain pro-rata earn-out payments, payable in common shares, to former shareholders of Purefarma as additional purchase consideration. These payments were based on Purefarma's ability to meet certain extraction-related cumulative gross margin targets, as follows:

Upon Purefarma achieving a cumulative gross margin of \$25,000,000 for the period commencing on December 14, 2018 and ending on December 31, 2023, the Company would issue 2,500,000 common shares to the former shareholders of Purefarma.

Upon Purefarma achieving a cumulative gross margin of \$50,000,000 for the period commencing on December 14, 2018 and ending on December 31, 2023, the Company would issue 3,500,000 common shares to the former shareholders of Purefarma.

Upon Purefarma achieving a cumulative gross margin of \$75,000,000 for the period commencing on December 14, 2018 and ending on December 31, 2023, the Company would issue 4,500,000 common shares to the former shareholders of Purefarma.

Upon Purefarma achieving a cumulative gross margin of \$100,000,000 for the period commencing on December 14, 2018 and ending on December 31, 2023, the Company would issue 5,500,000 common shares to the former shareholders of Purefarma; if Purefarma achieves such cumulative gross margin of \$100,000,000 before December 31, 2022, an additional 1,100,000 common shares would be issued to the former shareholders of Purefarma.

The total acquisition-date fair value of the equity-settled contingent consideration was apportioned in two. One portion was considered to be payable in a variable number of shares and was therefore classified as a financial liability. The remainder was considered to be payable in a fixed number of shares and was thus classified as equity. The balance being described in this note relates to the financial liability.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

16. Contingent Consideration Payable (continued)

(b) Contingent consideration issued in Purefarma acquisition, cash-settled

The Company was required to make certain performance payments, in cash, to a company controlled by the former shareholders of Purefarma as additional purchase consideration. The remaining performance payment was based on 3% of extraction-generated gross margin for Purefarma's fiscal year 2022, immediately prior to the Company's settlement of total Purefarma contingent consideration payable during the year ended October 31, 2022 (the "Settlement") as disclosed below.

Prior to the acquisition during the Company's year ended October 31, 2019, the fiscal year end of Purefarma was December 31st. Purefarma's fiscal year end was then changed to coincide with that of the Company. As a result, a pro-rated catch-up payment would have been required in December of 2022, if not settled during the year ended October 31, 2022.

Additional performance payments may be required based on certain geographical scope parameters.

As at October 31, 2021 and immediately prior to the Settlement, \$48,831 was outstanding from a corporation controlled by the former shareholders of Purefarma, including an active director of the Company. The director has the ability to exercise significant influence over the corporation in question. This balance was intended to be offset against the first payment made under the terms of the contingent consideration detailed above. The balance was unsecured, non-interest bearing, had no fixed terms of repayment and was included in other current asset in the consolidated statement of financial position.

As at October 31, 2022, Heritage issued 14,728,762 shares to former shareholders of Purefarma and applied the aforementioned \$48,831 receivable against the contingent consideration payable, as intended, to settle all the outstanding equity-settled and cash-settled contingent consideration payable issued in Purefarma acquisition. The 14,728,762 shares were measured at a fair value of \$515,507 determined based on the quoted market price on the date of issuance (Note 18(b)). Immediately prior to the Settlement, the Company revalued the contingent consideration payable to \$564,338, representing the sum of the fair value of common shares to be issued and the other receivable settled described above, with a recognition of loss from remeasurement of \$319,162 in profit or loss.

(c) Contingent consideration issued in Heritage West acquisition, cash-settled

In October of 2014, the Company entered into an agreement with the non-controlling shareholder of Heritage West, the terms of which state that the non-controlling shareholder had the right to require the Company to purchase from its certain preferred shares in Heritage West. The non-controlling shareholder had the ability to exercise this right upon Heritage West meeting certain license procurement and the cumulative earnings before interest, taxes, depreciation and amortization ("EBITDA") milestones of \$1,500,000 and \$2,500,000, respectively. If all milestones were met and the non-controlling shareholder exercised its right, the Company would be required to purchase these shares for total consideration of \$550,000.

During the year ended October 31, 2019, the first milestone of the license procurement was reached and the Company paid total proceeds of \$150,000 in cash to purchase 150,000 preferred shares in Heritage West from the non-controlling shareholder.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

16. Contingent Consideration Payable (continued)

(c) Contingent consideration issued in Heritage West acquisition, cash-settled (continued)

As at October 31, 2022, management settled all the contingent consideration payable issued in Heritage West acquisition as part of Heritage's purchase of additional non-controlling interest in Heritage West (the "NCI purchase") (Note 20). Immediately prior to the NCI purchase in Heritage West, management recognized the fair value of the contingent consideration payable in an amount of \$400,000, reflecting a high probability of meeting the remaining EBITDA milestones (2021 - \$345,000). At the NCI purchase date, the difference between the fair value of Heritage West contingent consideration payable settled, the fair value of the consideration paid and the carrying amount of the non-controlling interest was transferred into the retained earnings of the Company (Note 20).

(d) Contingent consideration issued in Premium 5 acquisition, equity-settled

As detailed in Note 4, the Company is required to issue additional Heritage Common Shares to former shareholders of Premium 5 for the First and Second Performance Milestone within the twenty-four months following the acquisition date.

As at October 31, 2021, the Company recognized the fair value of the First Performance Milestone payment in an amount of \$15,000,000, which represented the maximum pay-out for such milestone given the Company has exceeded the milestone expectations by January 25, 2022. As at October 31, 2022, the Company issued 107,142,857 Heritage Common Shares as full payment for First Performance Milestone, with a fair value of \$6,428,571 determined based on the quoted market price on the date of issuance (see Note 18(b)). Immediately prior to such settlement, the Company revalued the First Performance Milestone to \$6,428,571, representing the fair value of common shares to be issued described above, with a recognition of gain from remeasurement of \$8,571,429 in profit or loss. The number of common shares issued reflected the intended maximum pay-out amount of \$15,000,000 divided by the deemed value of \$0.14 per share.

As at October 31, 2022, the Company re-valued the fair value of Second Performance Milestone payment to \$nil (2021 - \$940,000), and recorded a gain from remeasurement of \$940,000 in profit or loss, based on the probability of meeting gross margin targets across all recreational products by January 25, 2023.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

16. Contingent Consideration Payable (continued)

The following is a continuity of contingent consideration payable:

	Pu	refarma	Herita	ige West	F	Premium 5	Total
Balance as at October 31, 2020	\$	1,110,311	\$	400,000	\$	-	\$ 1,510,311
Addition from Premium 5							
acquisition (Note 4)		-		-		11,505,000	11,505,000
Unrealized loss (gain) from							
changes in fair value		(865, 135)		(55,000)		4,435,000	3,514,865
Balance as at October 31, 2021	\$	245,176	\$	345,000	\$	15,940,000	\$ 16,530,176
First Performance Milestone							
payment for Premium 5							
acquisition		-		-		(6,428,571)	(6,428,571)
Settlement as part of NCI							
purchase in Heritage West		-		(400,000)		-	(400,000)
Purefarma contingent							
consideration payment							
through share issuance and		(564,338)		_		-	(564,338)
other receivable settled							
Unrealized loss (gain) from							
changes in fair value		319,162		55,000		(9,511,429)	(9,137,267)
Balance as at October 31, 2022	\$	-	\$	-	\$	-	\$ _

The Company's contingent consideration payable is measured at fair value based on unobservable inputs and is considered a level 3 financial instrument. Refer to Note 26.

17. Derivative liabilities

	Heritage (Cannabis	Heritage Can	nabis		
	Exchang	ge Corp.	Holdings Co	orp.		
	(a	1)	(b)		Tot	al
Balance as at October 31, 2020	\$	893,377	\$	-	\$	893,377
Addition		-	8	17,500		817,500
Interest expense		-		4,364		4,364
Unrealized loss (gain) from						
changes in fair value		(600,168)	3	63,396		(236,772)
Balance as at October 31, 2021	\$	293,209	\$ 1,1	85,260	\$	1,478,469
Addition		-	1,0	37,770		1,037,770
Interest expense		-	2	80,380		280,380
Unrealized loss (gain) from						
changes in fair value		(282,390)		68,067		(214,323)
Balance as at October 31, 2022	\$	10,819	\$ 2,5	571,477	\$	2,582,296
Less: current portion		-	(1,63	36,766)	(1,636,766)
Long-term portion	\$	10,819	\$ 9	934,711	\$	945,530

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

17. Derivative liabilities (continued)

(a) Heritage Cannabis Exchange Corp.

On October 6, 2020, the Company, through its wholly owned subsidiary Heritage Cannabis Exchange Corp. ("Purchaser Sub"), acquired all of the issued and outstanding shares of Opticann Inc. ("Opticann").

As part of the consideration for the acquisition of Opticann, Heritage Cannabis Exchange Corp. issued 7,919,493 warrants ("Class 1 Warrants"), exercisable for its Class A exchangeable shares at a price of \$0.20 per warrant for a period of 24 months from October 6, 2020, and 3,511,110 warrants ("Class 2 Warrants"), exercisable for its Class A exchangeable shares at a price of \$0.30 per warrant for a period of 36 months from October 6, 2020. The Class A exchangeable shares of the Purchaser Sub are redeemable and retractable into Heritage common shares on a 1:1 basis at the fair market value of a Heritage common share on the last business day prior to the redemption or retraction date at the option of the exchangeable shareholders ("Redemption/Retraction Price"). These warrants were considered to be exchangeable into a variable number of Heritage Common Shares and were therefore classified as financial liabilities measured at FVTPL. As at October 31, 2022, the Class 1 Warrants expired unexercised and were revalued immediately prior to expiry.

As at October 31, 2022, the Company re-valued the warrant derivative liabilities using a level 3 valuation technique, as detailed in Note 26 with the following inputs, assumptions and results, respectively:

At October 31, 2021	Class 1 Warrants	Class 2 Warrants
Number of warrants issued	7,919,493	3,511,110
Risk-free interest rate	1.08%	1.08%
Expected life (years)	0.93	1.93
Expected annualized volatility	89%	92%
Expected annual dividend yield	0.00%	0.00%
Exercise price	\$0.20	\$0.30
Share price	\$0.065	\$0.065
Calculated fair value per warrant at year-end	\$0.02	\$0.04

	Class 1 Warrants	
At October 31, 2022	(immediately prior to expiry)	Class 2 Warrants
Number of warrants issued	7,919,493	3,511,110
Risk-free interest rate	3.92%	3.92%
Expected life (years)	0.00	0.93
Expected annualized volatility	122%	142%
Expected annual dividend yield	0.00%	0.00%
Exercise price	\$0.20	\$0.30
Share price	\$0.030	\$0.035
Calculated fair value per warrant at the earlier		
of the expiry date or year-end	\$0.000	\$0.003

Expected annualized volatility was estimated using the Company's average historical volatility for a time period equal to the Class 1 and 2 Warrants' remaining terms, respectively.

The following table summarizes warrant activities in Heritage Cannabis Exchange Corp. during the years ended October 31, 2022 and 2021:

	Number of warrants	Weighted average exercise price		
Balance as at October 31, 2020 and 2021	11,430,603	\$ 0.23		
Expired	(7,919,493)	0.20		
Balance as at October 31, 2022	3,511,110	\$ 0.30		

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

17. Derivative liabilities (continued)

(b) Heritage Cannabis Holdings Corp., the parent company

On October 18, 2021, the Company entered into a note and warrant purchase agreement (the "Agreement") with two lenders, each to provide the Company \$750,000 USD for an aggregate funding of \$1,500,000 USD. The \$1,500,000 USD is to be disbursed in four tranches from October 18, 2021 through December 31, 2021. At closing of each disbursement, the Company will issue to the lender a convertible promissory note (each, a "Note" and together, the "Notes") and a warrant (each, a "Warrant" and together, the "Warrants").

The Notes mature in 24 months from the effective date and bear an interest rate of 15% per annum, which shall be paid in common shares of the Company ("Heritage Common Shares") (such shares issuable as interest payment, the "Interest Shares"). The price per Interest Share shall be the greater of: (i) 90% of the volume weighted average price per Heritage Common Share for the five consecutive trading days preceding such issuance, and (ii) the minimum price per Heritage Common Share permitted pursuant to applicable securities laws and the requirements of the Canadian Securities Exchange ("CSE"). The Interest Shares shall be issued on a quarterly basis, beginning on January 18, 2022. The principal amount is due and payable upon maturity in cash or Heritage Common Shares (the "Conversion Shares") at the option of Notes holders. The conversion price per Conversion Share shall be the greater of: (i) the closing market share price of the Heritage Common Shares on the trading day prior to a news release or the posting of notice to the CSE website, and (ii) \$0.07 CDN. As at October 31, 2022, no Interest Shares have yet been issued.

The Warrants issuable are exercisable for a period of 36 months from the issuance dates. Each Warrant is exercisable into Heritage Common Shares (the "Warrant Shares"), equal to 50% of the aggregate number of Conversion Shares that would be received upon the holder's conversion of 100% of the aggregate amount of principal outstanding under the Note. Exercise price per Warrant Shares shall be the greater of: (i) the closing market share price of the Heritage Common Shares on the trading day prior to a news release or the posting of notice to the CSE website, and (ii) \$0.083 CDN.

Both the Notes and Warrants were considered to be exercisable into a variable number of Heritage Common Shares due to the variable conversion price, and therefore were classified together as a financial liability at FVTPL.

As at October 31, 2022, the Company received all tranches of \$1,500,000 USD (equivalent to \$1,855,270 CDN) in total principal, and issued a Note and Warrant upon the cash receipt per tranche. At initial recognition of each tranche, the Company allocated the proceeds received to the Note and the Warrant based on their relative fair value at the issuance date. The standalone fair value of the Note was calculated using the effective interest rate of 15% implicit in the Note. The standalone fair value of the Warrant was calculated using a level 3 valuation technique as detailed in Note 26. As at October 31, 2022, the Company revalued all the Notes at fair value, calculated as the greater of the amount payable in equity and the amount payable in cash if no conversion right is exercised. The Warrants were re-valued at fair value using the same valuation technique as that used for initial recognition with the following inputs, assumptions and results:

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

17. Derivative liabilities (continued)

Expected annual dividend yield

Calculated standalone fair value per Warrant

Exercise price

Share price

(b) Heritage Cannabis Holdings Corp., the parent company (continued)

m 1 4	As at	As at
Tranche 1	October 31, 2021	October 31, 2022
Estimated number of Warrant Shares issuable	5,834,400	6,434,528
Risk-free interest rate	1.14%	3.92%
Expected life (years)	2.97	1.97
Expected annualized volatility	91%	114%
Expected annual dividend yield	0.00%	0.00%
Exercise price	\$0.08	\$0.08
Share price	\$0.065	\$0.035
Calculated standalone fair value per Warrant	\$363,637	\$90,708
	As at November 1,	As at
Tranche 2	2021, the issuance date	October 31, 2022
Estimated number of Warrant Shares issuable	3,317,142	3,655,982
Risk-free interest rate	1.14%	3.92%
Expected life (years)	3	2.00
Expected annualized volatility	91%	113%
Expected annual dividend yield	0.00%	0.00%
Exercise price	\$0.08	\$0.08
Share price	\$0.065	\$0.035
Calculated standalone fair value per Warrant	\$113,313	\$51,881
Calculated standarone ran value per vvairant	ψ113,313	ψ31,001
	As at November 30,	As at
Tranche 3	2021, the issuance date	October 31, 2022
Estimated number of Warrant Shares issuable	2,998,125	3,655,982
Risk-free interest rate	1.07%	3.92%
Expected life (years)	3	2.08
Expected annualized volatility	91%	116%
Expected annual dividend yield	0.00%	0.00%
Exercise price	\$0.08	\$0.08
Share price	\$0.080	\$0.035
Calculated standalone fair value per Warrant	\$136,271	\$55,563
	As at December 31,	As at
Tranche 4	2021, the issuance date	October 31, 2022
Estimated number of Warrant Shares issuable	815,014	877,435
Risk-free interest rate	1.02%	3.92%
Expected life (years)	3	2.17
Expected annualized volatility	91%	114%
	0.0004	0.0004

0.00%

\$0.08

\$0.065

\$27,696

0.00%

\$0.08

\$0.035

\$13,487

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

17. Derivative liabilities (continued)

(b) Heritage Cannabis Holdings Corp., the parent company (continued)

Expected annualized volatility was estimated using the Company's average historical volatility for a time period equal to the Warrants' remaining terms at valuation dates.

Below is a reconciliation of changes in the fair value of the Notes and the Warrants:

	Notes	Warrants	Total
Balance as at October 31, 2020	\$ -	\$ -	\$ -
Additions	602,837	214,663	817,500
Interest expense	4,364	-	4,364
Unrealized (gain) loss from changes			
in fair value	214,422	148,974	363,396
Balance as at October 31, 2021	\$ 821,623	\$ 363,637	\$ 1,185,260
Additions	822,150	215,620	1,037,770
Interest expense	280,380	-	280,380
Unrealized (gain) loss from changes			
in fair value	435,685	(367,618)	68,067
Balance as at October 31, 2022	\$ 2,359,838	\$ 211,639	\$ 2,571,477

The following table summarizes warrant activities for warrants classified as financial liabilities at FVTPL during the years ended October 31, 2022 and 2021:

	Number of warrants
Balance as at October 31, 2021	1
Issued	3
Balance as at October 31, 2022	4

In connection with the Agreement, the Company paid commitment fees of \$76,663 through an issuance of 1,393,884 Heritage Common Shares at initial closing. See Note 18(b).

18. Share capital

(a) Authorized share capital

The Company is authorized to issue an unlimited number of common shares without par value.

(b) Issued share capital

During the year ended October 31, 2022, the following share issuances took place:

On November 4, 2021, the Company issued 29,809 common shares as a result of warrant exercises at an exercise price of \$0.7 for total cash proceeds of \$20,866. The warrants were allocated \$nil value based on residual method upon issuance as part of a private placement, and therefore \$nil warrant reserve was transferred to share capital upon exercise.

On January 25, 2022, the Company issued 107,142,857 common shares to Premium 5 former shareholders as its First Performance Milestone payment in full (See Note 16(d)). The fair value of the common shares was measured at \$6,428,571, determined based on the quoted share price at the issuance date.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

18. Share capital (continued)

(b) Issued share capital (continued)

On June 3, 2022, the Company agreed to settle legal costs owing by certain Opticann former shareholders to a third party in the amount of \$140,000, which was included in the accounts payable and accrued liabilities in the statement of financial position as at October 31, 2022. In exchange, the Company cancelled 933,333 common shares held by these Opticann former shareholders. The original carrying amount of the cancelled common shares in the amount of \$126,000 was recorded as a reduction from share capital, with the difference of \$14,000 between the amount of liabilities assumed and the carrying amount of cancelled common shares aforementioned recorded as a decrease in contributed surplus. No gain or loss was recognized on this transaction.

On June 17, 2022, the Company issued 7,109,090 common shares to certain executives and consultants as compensation bonus, of which 3,745,454 common shares were issued to key management (Note 22). The fair value of common shares issued was measured at \$355,455 determined based on the quoted share price of \$0.05 per share at the issuance date.

On September 15, 2022, the Company issued 2,000,000 common shares as part of the purchase consideration for the acquisition of additional non-controlling interest in Heritage West. The fair value of common shares issued was measured at \$70,000 determined based on the quoted share price of \$0.035 per share at the issuance date (Note 20).

On September 15, 2022, the Company issued 14,728,762 common shares for the settlement of all the outstanding equity-settled and cash-settled Purefarma contingent consideration payable (Note 16 (b)). The fair value of common shares issued was measured at \$515,507 determined based on the quoted share price of \$0.035 per share at the issuance date.

During the year ended October 31, 2021, the following share issuances took place:

On November 12, 2020, the Company issued 2,549,644 common shares as a result of 2,549,644 options exercised at an exercise price of \$0.10. Total proceeds of \$250,000 were credited to share capital, in addition to the transfer of \$578,259 from contributed surplus. Refer to Note 19(b).

On January 15, 2021, the Company issued 5,076,628 restricted shares, of which 2,191,831 were issued as compensation bonus with a fair value of \$350,693, determined based on the closing share price of Heritage Common Shares at the issuance date, and 2,884,797 of which were issued as settlement of key management compensation in the amount of \$342,142. There was no gain or loss recognized on the debt settlement, as the key management are also shareholders of the Company. All of the restricted shares vested immediately, resulting in an issuance of 5,076,628 Heritage Common Shares.

On January 31, 2021 and April 11, 2021, as part of the purchase consideration for the Premium 5 acquisition as described in Note 4, the Company issued a total of 150,000,000 and 30,156,643 common shares, respectively. The fair value of these shares was measured at \$30,626,629, determined based on the closing share price of the Company at the acquisition date.

On March 17, 2021, the Company issued 98,900,000 units (each, a "Unit"), at a price of \$0.14 per unit for aggregated gross proceeds of \$13,846,000. Each Unit consists of one common share and one common share purchase warrant (each, a "Warrant"). Each Warrant is exercisable for one common share at any time for a period of 24 months ending on March 17, 2023 at an exercise price of \$0.21 per Warrant. The proceeds were first allocated to the common shares in accordance with the residual method, resulting in \$nil being allocated to the warrants. The Company paid issuance costs of \$1,344,665 in cash and \$598,392 through the issuance of 6,923,000 broker warrants (each, "Broker Warrants"). Each Broker Warrant is exercisable into one Unit at a price of \$0.14 per unit, expiring on March 17, 2023. The value of the Broker Warrants was measured based on the fair value of the equity instruments granted.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

18. Share capital (continued)

(b) Issued share capital (continued)

On April 15, 2021, the Company issued 170,000 common shares to a financing agent for the services rendered in relation to the refinance agreement. Upon the issuance, the Company recognized a gain on the debt settlement of \$5,900, arising from the difference between the service fees of \$28,000 settled and the value of shares measured based on the quoted market price on the date of issuance.

On May 4, 2021, the Company issued 495,049 common shares in consideration for certain advisory services received. The fair value of these shares was measured at \$54,455, determined based on the quoted market price on the date of issuance.

On September 29, 2021, the Company issued 1,250,000 common shares in consideration for certain marketing services received. The fair value of these shares was measured at \$75,000, determined based on the quoted market price on the date of issuance.

On October 19, 2021, the Company issued 1,393,884 common shares for commitment fees related to the Agreement detailed in Note 17(b). The fair value of these shares was measured at \$76,663, determined based on the quoted market price on the date of issuance.

19. Contributed surplus

(a) Warrants

Movements in the number of warrants outstanding during the year ended October 31, 2022 and 2021 are as follows:

	Number of	Weighted av	erage
	warrants	exercise pr	rice
Balance as at October 31, 2020	31,281,960	\$	0.54
Issued as part of March 2021 private placement (Note 18(b))	98,900,000		0.21
Issued as settlement of share issuance costs (Note 18(b))	6,923,000		0.14
Issued as part of loan amendment (Note 15(b))	10,000,000		0.25
Expired	(12,666,260)		0.35
Balance as at October 31, 2021	134,438,700	\$	0.27
Issued as part of loan amendment (Note 15(b))	50,000,000		0.10
Exercised (Note 18(b))	(29,809)		0.70
Expired	(18,585,891)		0.68
Balance as at October 31, 2022	165,823,000	\$	0.18

The fair value of modified warrants and issued warrants as part of the second loan amendment (Note 15(b) during the year ended October 31, 2022 was determined at the time of issuance using the Black-Scholes option pricing model with the following weighted average inputs, assumptions and results:

	Modified warrants	Issued warrants
Risk-free annual interest rate	3.79%	3.79%
Expected life (years)	2.42	2.42
Expected annualized volatility	105%	105%
Expected annual dividend yield	0.00%	0.00%
Exercise price	\$0.25	\$0.10
Share price	\$0.035	\$0.035
Calculated fair value per warrant at grant date	\$0.01	\$0.01
Number of warrants	10,000,000	50,000,000

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

19. Contributed surplus (continued)

(a) Warrants (continued)

The fair value of warrants issued during the year ended October 31, 2021 for issuance costs was determined at the time of issuance using the Black-Scholes option pricing model with the following weighted average inputs, assumptions and results:

Risk-free annual interest rate	0.27%
Expected life (years)	2
Expected annualized volatility	91%
Expected annual dividend yield	0.00%
Exercise price	\$0.14
share price	\$0.14
Calculated fair value per warrant at grant date	\$0.09

Expected annualized volatility was estimated using the Company's average historical volatility for a time period equal to the warrants' expected life.

See Note 15(c) and Note 18(b) for the valuation of warrants issued as part of loan amendment and private placement during the year ended October 31, 2021, respectively.

The following table summarizes the warrants outstanding and exercisable as at October 31, 2022:

Number of		Weighted a	verage
Expiry date	warrants	exercise 1	price
March 17, 2023	98,900,000	\$	0.21
March 17, 2023	6,923,000		0.14
February 28, 2025 (Note 15(b))	10,000,000		0.25
February 28, 2025 (Note 15(b))	50,000,000		0.10
	165,823,000	\$	0.18

Of the 165,823,000 warrants outstanding, 6,923,000 are broker warrants and 158,900,000 are standard common share purchase warrants. Broker warrants are exercisable into units of the Company; in turn, each unit comprises one common share and either a whole or partial common share purchase warrant.

(b) Stock options

(i) Stock option plan details

The Company has adopted an incentive stock option plan, which provides that the Board of Directors of the Company may from time to time, in its discretion and in accordance with the Canadian Stock Exchange requirements, grant to directors, officers, employees and technical consultants to the Company, non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares of the Company. Options will be exercisable for a period to be determined by the Board of Directors, but not exceeding 10 years.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

19. Contributed surplus (continued)

- (b) Stock options (continued)
- (i) Stock option plan details (continued)

In connection with the foregoing, the number of common shares reserved for issuance to any technical consultant will not exceed two percent (2%) of the issued and outstanding common shares of the Company in any twelve-month period. The number of common shares reserved for issuance to individuals providing investor relation services will not exceed two percent (2%) of the issued and outstanding common shares of the Company in any twelve-month period. Furthermore, these options must vest over twelve months with a maximum of one quarter of the options vesting in any three-month period. Options may be exercised no later than 90 days following cessation of the optionee's position with the Company, provided that if the cessation of office, directorship, or technical consulting arrangement was by reason of death, the option may be exercised within a maximum period of one year after such death, subject to the expiry date of such option.

Movements in the number of options outstanding during the year ended October 31, 2022 are as follows:

	Weighted average			
	Number of options	exercise p	rice	
Balance as at October 31, 2021	24,763,440	\$	0.19	
Expired	(2,000,000)		0.10	
Forfeited	(410,000)		0.26	
Balance as at October 31, 2022	22,353,440	\$	0.20	

Movements in the number of options outstanding during the year ended October 31, 2021 are as follows:

		Weighted average		
	Number of options		rice	
Balance as at October 31, 2020	13,838,084	\$	0.28	
Granted	13,875,000		0.10	
Exercised	(2,549,644)		0.10	
Expired	(400,000)		0.34	
Balance as at October 31, 2021	24,763,440	\$	0.19	

The fair value of stock options issued during the year ended October 31, 2021 was determined at the time of issuance using the Black-Scholes option pricing model with the following weighted average inputs, assumptions and results:

Risk-free annual interest rate	1.11%
Expected life (years)	5
Expected annualized volatility	146%
Expected annual dividend yield	0.00%
Exercise price	\$0.10
Share price at grant date	\$0.07
Calculated fair value per option at grant date	\$0.06

Expected annualized volatility was estimated using the Company's average historical volatility for a time period equal to the options' expected life terms.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

19. Contributed surplus (continued)

(b) Stock options (continued)

The following table summarizes the options outstanding and exercisable at October 31, 2022:

	Number of options	Number of options	Weighted average
Expiry date	outstanding	exercisable	exercise price
November 15, 2022	80,000	80,000	\$ 0.14
January 22, 2023	700,000	700,000	0.59
March 19, 2023	861,000	861,000	0.54
April 30, 2023	850,000	850,000	0.35
August 20, 2023	254,964	254,964	0.20
April 10, 2025	892,476	892,476	0.20
February 8, 2024	3,750,000	3,750,000	0.34
September 20, 2024	1,250,000	1,250,000	0.36
September 17, 2026	13,715,000	9,143,333	0.10
	22,353,440	17,781,773	\$ 0.20

As at October 31, 2022, the weighted average remaining contractual life of all options outstanding was 2.85 years (2021 - 3.60 years). The weighted average exercise price for exercisable options was \$0.23 (2021 - \$0.25).

(i) Amounts arising from share-based payment transactions

During the year ended October 31, 2022, the Company recognized an expense of \$389,895 relating to the vesting of options held by employees, directors, officers and consultants (2021 - \$342,123). The Company also accrued a share-based payment of \$24,745 (2021 - \$nil) relating to sales staff shares to be issued (Note 31).

(c) Restricted shares

During the year ended October 31, 2022, there were no movements in restricted shares.

During the year ended October 31, 2021, the Company granted 5,076,628 restricted common shares to key management. These restricted shares vested immediately at the grant date, resulting in the issuance of 5,076,628 common shares detailed in Note 18(b).

During the year ended October 31, 2022, the Company recorded share-based payments of \$nil (2021 - \$350,693) for the vesting of restricted shares.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

20. Non-controlling interest

On September 15, 2022, the Company paid \$50,000 in cash and issued 2,000,000 Heritage Common Shares measured at \$70,000 as detailed in Note 18(b) as total consideration for its purchase of 500 common shares and 400,000 preferred shares in Heritage West from the non-controlling shareholder. As a result of the NCI purchase, the entire contingent consideration payable issued in Heritage West acquisition was settled (Note 16(c)), and the Company increased its interest in Heritage West and Mainstrain Market Ltd. ("Mainstrain") from 75% to 100%.

At the NCI purchase date, the difference of \$1,875,040 between the carrying amount of the non-controlling interest (the "NCI") at \$1,595,040, the fair value of contingent consideration payable settled at \$400,000 in Heritage West (Note 16(c)) and the fair value of the consideration paid at \$120,000 was transferred into the retained earnings of the Company.

The following table presents the summarized financial information for Heritage West and Mainstrain, the Company's subsidiaries which each had NCI of 25% immediately prior to September 15, 2022, the NCI purchase date. This information represents amounts before intercompany eliminations for the stub period from November 1, 2021 to September 14, 2022, and as at September 14, 2022. NCI was measured at fair value at the acquisition date.

		Heritage West	Mainstrain	
Current assets	\$	\$ 24,791,989		19
Non-current assets		6,599,343		-
Current liabilities		28,804,207	1	46,581
Non-current liabilities		-		-
Net revenue		25,621,765		-
Net income (loss) and comprehensive income (loss)		3,823,176		(1,126)

The following table presents the summarized financial information before intercompany eliminations for the year ended and as at October 31, 2021.

		Heritage West	Mainstrain	
Current assets	\$	11,075,121	\$	-
Non-current assets		6,730,549		-
Current liabilities		14,627,465		145,436
Non-current liabilities		14,098		-
Net revenue		18,672,625		-
Net income (loss) and comprehensive income (loss)		472,617		(483)

The net changes in non-controlling interest are as follows:

	Heritage Wes	t :	Mainstrain	Total
Balance as at October 31, 2020	\$ 627,521	\$	12,665	\$ 640,186
Share of income (loss)	118,154		(120)	118,034
Share of amortization of Heritage West licenses				
acquired through business combination (Note 12)	(63,338)		-	(63,338)
Balance as at October 31, 2021	\$ 682,337	\$	12,545	\$ 694,882
Share of income (loss)	955,794		(282)	955,512
Share of amortization of Heritage West licenses				
acquired through business acquisitions (Note 12)	(55,355)		-	(55,355)
Decrease in NCI	(1,582,776)		(12,263)	(1,595,039)
Balance as at October 31, 2022	\$ -	\$	-	\$ -

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

21. Income taxes

The Company's combined Canadian federal and provincial statutory income tax rate is 26.5% for the year ended October 31, 2022 and 2021. The Company's provision for income taxes for the years ended October 31, 2022 and 2021 differs from the amounts computed by applying the combined Canadian federal and provincial income tax rates to the net and comprehensive loss as a result of the following:

	2022	2021
Income tax expense (recovery) at statutory rate	\$ (615,000)	\$ (5,244,000)
Non-deductible and non-taxable permanent differences	266,000	103,000
Financing fees charged to equity and debt	(472,000)	(458,000)
Unrealized gain or loss on contingent consideration payable,		
derivative liabilities, and investments	(2,678,000)	888,000
Income tax benefits not recognized and other	824,000	1,692,040
Provision for income taxes	\$ (2,675,000)	\$ (3,018,960)

Deferred tax assets and liabilities have been offset where they relate to income taxes levied by the same taxation authority and the Company has the legal right and intent to offset.

Balance as at October 31, 2020	\$ 5,336,000
Deferred tax liability assumed from business combination (Note 5)	2,288,960
Deferred income tax recovery	(3,018,960)
Balance as at October 31, 2021	4,606,000
Deferred income tax recovery	(2,675,000)
Balance as at October 31, 2022	\$ 1,931,000

The tax effects of temporary timing differences that give rise to significant components of the Company's deferred tax assets and liabilities for the years ended October 31, 2022 and 2021 were as follows:

	2022		2021	
Deferred tax assets (liabilities)				
Non-capital loss carry forward	\$	15,495,000	\$	12,081,000
Inventories		(344,000)		(28,000)
Property, plant and equipment		(194,000)		60,000
Lease liabilities		176,000		197,000
Financing costs		666,000		371,000
Intangible assets		(5,096,000)		(10,153,000)
Share issuance costs		490,000		772,000
Resource deductions		280,000		280,000
Contingent consideration payable		-		(705,000)
Other		415,000		367,000
		11,888,000		3,242,000
Less: Tax assets not recognized		(13,819,000)		(7,848,000)
Deferred tax liability	\$	(1,931,000)	\$	(4,606,000)

The Company has accumulated non-capital losses for Canadian tax purposes of approximately \$58,376,000 which may be carried forward and used to reduce taxable income in future years. The accumulated non-capital losses expire as follows:

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

21. Income taxes (continued)

Year of Expiry	Amount
2028	\$ 81,000
2029	148,000
2030	247,000
2031	267,000
2032	187,000
2033	422,000
2034	711,000
2035	486,000
2036	498,000
2037	2,093,000
2038	5,725,000
2039	9,808,000
2040	7,322,000
2041	15,729,000
2042	14,652,000
	\$ 58,376,000

The Company has cumulative Canadian exploration and development expenses in the amount of approximately \$1,039,000, which can be carried forward indefinitely. No benefit has been recognized in respect of these amounts.

22. Related party transactions and balances

All amounts either due to or from related parties, unless disclosed otherwise, are non-interest bearing, unsecured and due on demand. Transactions undertaken with related parties during the years ended October 31, 2022 and 2021 are as follows:

(a) Transactions with directors, officers and companies controlled by directors, officers and/or their families

		Year ended October 31,		
		2022		2021
Management fees	\$	50,000	\$	194,000
Consulting fees		269,000		391,311
	\$	319,000	\$	585,311
	-	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	·	
(b) Key management compensation		Year ended	October 3	1,
(b) Key management compensation				1, 2021
(b) Key management compensation Salary and short-term benefits		Year ended		
		Year ended 2022	2	2021

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

22. Related party transactions and balances (continued)

(b) Key management compensation (continued)

During the year ended October 31, 2021, the Company issued 5,076,628 restricted common shares to key management, partly as settlement of unpaid compensation and partly as compensation bonus. Refer to Note 18(b). The Company also issued 13,875,000 options, of which 4,800,000 options were issued to key management. Refer to Note 19(b).

(c) Related party balances

	As at		As at	
	Octol	per 31, 2022	October :	31, 2021
Included in accounts payable and accrued liabilities	\$	198,350	\$	27,229
Included in other current asset (Note 16(b))		-		48,831

23. Commitments

As detailed in Note 17(a), the Company acquired Opticann on October 6, 2020. The remaining purchase consideration payable for the acquisition includes:

- (a) 100,000,000 Class B exchangeable shares of Purchaser Sub, which were issued upon acquisition and are redeemable and retractable, subject to conditions including Opticann's ability to meet certain cumulative gross margin targets within required time periods and to enter into distribution, supply, or collaboration agreements (or similar) with certain vendors, into Heritage Common Shares on a 1:1 basis at the Redemption/Retraction Price at the option of the exchangeable shareholders.
- (b) Contingent performance payments, payable in Heritage Common Shares, partly based on a fixed percentage of the funds invested in the Company in cash or assets up to certain amounts by certain vendors, partly upon the Company's ability to achieve certain cumulative sales or gross margin targets, and partly upon the acquisition of a supplier.

The acquisition was accounted for as an asset acquisition, given Opticann did not meet the definition of business at the acquisition date in accordance with IFRS 3. As at October 31, 2022 and 2021, no provision was recognized in relation to the above Class B exchangeable shares or contingent performance payments, given none of their payment milestones were met.

In addition, as consideration for the acquisition of Opticann license, the Company is committed to make the remaining payments, including:

- (a) \$2,600,000 USD payable upon the Company's achievement of certain milestones, including its receipt of first purchase order for certain goods and reaching \$2,000,000 USD and \$1,000,000 CDN sales of certain goods, respectively;
- (b) Royalty payment of 20% on all gross margins from the sale of certain goods, payable quarterly;
- (c) Additional milestone payments, calculated as 10% of the value of any upfront milestone payments received by the Company for certain agreements with certain parties and 15% of the gross margin received on net sales as a result of certain agreements between the Company and certain parties; and
- (d) Dedication of a minimum 11% of net sales per year for marketing activities, which commences at the same time as the purchase right noted below.

The Company also has a right to purchase at least USD \$27,500,000 of certain goods from a supplier over 3 years from the first day of the month in which the Company received the purchase order for certain goods from any customer.

As at October 31, 2022 and 2021, none of the payment milestones were met and, therefore, no provision was recognized.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

24. Loss per share

Basic loss per share amounts are calculated by dividing the net loss attributable to common shareholders for the year by the weighted average number of common shares outstanding during the year. The basic and diluted loss per share amounts are the same as there are no instruments that have a dilutive effect.

25. Financial instruments

The Company is exposed to risks that arise from its use of financial instruments. This note describes the Company's objectives, policies and processes for managing those risks and the methods used to measure them. Further quantitative information pertaining to these risks is presented throughout these consolidated financial statements.

There have been no substantive changes in the Company's exposure to financial instrument risks, its objectives, policies and processes for managing those risks, or the methods used to measure them since October 31, 2021, unless otherwise stated.

(a) Credit risk

Credit risk is the risk of a potential loss to the Company if a customer or third party to a financial instrument fails to meet its contractual obligations. The Company has moderate exposure to credit risk from its cash, short-term investments, accounts receivable, and note receivable. The risk exposure is limited to their carrying amounts at the statement of financial position date. The risk for cash and short-term investments is mitigated by holding these balances with highly-rated Canadian financial institutions. The Company therefore does not expect any credit losses on its cash and short-term investments.

The Company's accounts receivable balance consists of the following:

	As at		As at	
	Octo	October 31, 2022		ber 31, 2021
Trade accounts receivable from customers	\$	7,798,057	\$	4,621,574
Expected credit losses		(353,420)		(91,194)
Net trade receivables		7,444,637		4,530,380
Interest and other receivables (Note 30)		43,480		242,905
	\$	7,488,117	\$	4,773,285

The Company provides credit to certain customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. Credit risk for customers is assessed on a case-by-case basis and a provision is recorded where required. As at October 31, 2022, the Company identified certain accounts that may result in a credit loss on its accounts receivable, for which expected credit losses were recognized.

The Company has assessed that there is a concentration of credit risk, as 68% of the Company's net trade accounts receivable is due from three customers as at October 31, 2022 (as at October 31, 2021 - 77% of the balance due from three customers).

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

25. Financial instruments (continued)

(a) Credit risk (continued)

An analysis of the aging of trade accounts receivable (net of allowance) is as follows:

	As at	As at October 31, 2022		As at
	October 31, 2			ber 31, 2021
Current (30 days or less)	\$ 4,37	1,452	\$	2,397,231
31-60 days	1,15	2,874		1,558,194
61-90 days	5	7,804		93,189
Greater than 90 days	1,86	2,507		481,766
	\$ 7,44	4,637	\$	4,530,380

(b) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet the financial obligations associated with its financial liabilities as they come due. The Company manages liquidity risk through the management of its capital structure. As at October 31, 2022, the Company had working capital of \$14,730,394 (as at October 31, 2021 – \$20,304,906). The Company does not yet have positive cash flows from operations and as such, the Company may be dependent upon the issuance of new equity and/or debt to advance its production efforts and meet its financial obligations. If equity or debt financing is required, failure to obtain such financing on a timely basis may cause the Company to postpone, reduce or terminate its production plans.

The Company has the following undiscounted contractual obligations subject to liquidity risk, in addition to those relating to lease liabilities disclosed in Note 14:

	<1 year	2-5years	> 5	years
Accounts payable and accrued liabilities	\$ 15,197,496	\$ -	\$	-
Long-term debt	7,023	16,816,039		-
Derivative liabilities with cash settlement				
option (Note 17(b))	1,412,672	634,679		-
Total	\$ 16,617,191	\$ 17,450,718	\$	-

(c) Market risk

(i) Foreign currency risk

Foreign currency risk is the risk that a variation in exchange rates between the Canadian dollar and other foreign currencies will affect the Company's operations and financial results. The Company is exposed to this risk on its investment in Endocanna (Note 11), an associate that bears the U.S. dollar as its functional currency. The Company is required to translate the financial position and operating results of Endocanna into Canadian dollars and to recognize its share of the resulting translation gain or loss in other comprehensive income or loss. The Company is further exposed to the foreign currency risk through Opticann, a wholly owned subsidiary operating in United States (Note 1(e)), and through its derivative liabilities denominated in USD (Note 17(b)). As at October 31, 2022 and October 31, 2021, the Company has not entered into any hedging agreements to mitigate foreign currency risk. As such, the Company's financial position and financial results may be adversely affected by the unfavorable fluctuations in foreign currency exchange rates.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

25. Financial instruments (continued)

(c) Market risk (continued)

(i) Foreign currency risk (continued)

The following table provides a summary of financial assets and liabilities denominated in USD:

	As at	As at
	October 31, 2022	October 31, 2021
Cash	\$ 4,030	\$ 3,579
Accounts receivable	659	659
Accounts payable and other liabilities	24,459	39,484
Investment in associate	2,355,039	2,459,747
Derivative liabilities	1,721,190	663,526

A 10% strengthening of the Canadian dollar against the foreign currencies listed above would increase other comprehensive loss by \$90,492 (2021 - \$382,481). A 10% weakening of the Canadian dollar against the foreign currencies listed above would result in an equal, but opposite effect.

(ii) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's short-term investments, convertible promissory note receivable and notes receivable earn fixed rates of interest in the range from 0.7% to 1.05% per annum, 2% per annum and 10% per annum respectively. The Company is exposed to this risk on its long-term debt, part of which bears variable interests as detailed in Note 15. As at October 31, 2022 and 2021, the Company had no hedging agreements in place.

(iii) Price risk

Price risk is the risk of variability in fair value due to movements in equity or market prices. As at October 31, 2022 and 2021, the Company is exposed to this risk on the derivative liabilities payable in Heritage Common Shares (Note 17(b)).

26. Fair value of financial instruments

Assets recorded at fair value in the statement of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets and liabilities;

Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly; and

Level 3 - valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

26. Fair value of financial instruments (continued)

Financial instruments are measured either at fair value or at amortized cost. The table below lists the valuation methods used to determine the fair value of each financial instrument.

Financial instruments measured at fair value	
Convertible promissory note receivable	Amount due on demand (Level 3)
Other investments	Market value (Level 3)
Notes receivable	Market value (Level 3)
Derivative liabilities	Market value (Level 3) or Black-Scholes model (Level 3)
Contingent consideration payable	Discounted cash flow (Level 3) or Black-Scholes model (Level 3)
Financial instruments measured at amortized cost	
Cash; Short-term investments; Accounts receivable; Other current asset; Accounts payable and accrued liabilities	Carrying amount (approximates fair value due to short-term nature)
Long-term debt	Carrying value at the effective interest rate which approximates fair value

During the year ended October 31, 2022 and 2021, there were no transfers of amounts between levels.

27. Entity-wide disclosures

The Company's trade net revenue for the year ended October 31, 2022 is comprised of the following:

	Domes	stic (Canada)
Net revenue from sale of Heritage branded products	\$	29,566,385
Net revenue from sale of White Label products		-
Net revenue from provision of services		
	\$	29,566,385

The Company's trade net revenue for the year ended October 31, 2021 is comprised of the following:

	Domestic (Canada	.)
Net revenue from sale of Heritage branded products	\$ 13,635,8	325
Net revenue from sale of White Label products	218,6	96
Net revenue from provision of services	204,6	i09
	\$ 14,059,1	30

During the year ended October 31, 2022, the Company earned 83% of its total trade revenue from four major customers (2021 - 75% from four major customers).

28. Operating segment information

During the year ended October 31, 2022 and 2021, the Company identified a single reportable operating segment.

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

29. Capital management

The Company manages its cash, short-term investments, common shares, stock options and share purchase warrants as capital. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue the development of a cannabis production business and to maintain a flexible capital structure which optimizes the cost of capital at an acceptable risk level.

The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may attempt to issue new shares, issue new debt, acquire or dispose of assets or adjust the amount of cash and short-term investments on hand.

In order to facilitate the management of its capital requirements, the Company prepares annual budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions. The annual and updated budgets are approved by the Board of Directors.

In order to maximize ongoing production efforts, the Company does not pay out dividends. The Company's investment policy is to invest its short-term excess cash in highly liquid short-term interest-bearing investments, selected with regards to the expected timing of expenditures from continuing operations.

Management considers its approach to capital management to be appropriate given the relative size of the Company. There were no changes in the Company's approach to capital management during the reporting period.

30. Government grant

As a response to the COVID-19, the Canadian Federal government introduced CEWS for qualifying businesses, which suffered a drop in gross revenues by a certain amount from March 2020. The purpose of the CEWS is to support businesses and employers to continue to employ workers or to re-hire workers that were previously laid off. The CEWS is considered as a form of government grant.

During the year ended October 31, 2021, the Company had not applied for any additional CEWS. As a result of CEWS applied in prior year, \$nil (2021 - \$133,243) was included in accounts receivable as at October 31, 2022.

31. Supplementary cash flow information

The net changes in non-cash working capital items for the years ended October 31, 2022 and 2021 are as follows:

	2022	2021
Sales tax recoverable	\$ 804,348	\$ (845,954)
Accounts receivable	(2,714,832)	(3,427,115)
Inventories	521,150	(8,059,636)
Prepaid expenses and deposits	333,763	(1,587,918)
Other current asset	-	369,630
Other investments and deposits	(503,113)	(285,660)
Accounts payable and accrued liabilities	7,247,290	4,648,603
Sales tax payable	243,243	(97,633)
Deferred revenue	440,843	239,799
Net changes in non-cash working capital	\$ 6,372,692	\$ (9,045,884)

Notes to Consolidated Financial Statements For the Years ended October 31, 2022 and 2021 (Stated in Canadian Dollars)

32. Subsequent events

(a) Amalgamation between CALYX and Purefarma

On November 1, 2022, CALYX and Purefarma were amalgamated, with Purefarma as the resulting amalgamated company.

(b) Expiry of options

On November 15, 2022, 80,000 options expired unexercised.

(c) Equity financing with Obsidian Global Partners, LLC

On November 1, 2022, the Company entered into an equity line of credit agreement (the "ELOC Agreement" with Obsidian Global Partners, LLC (the "Investor") whereby the Investor proposes to purchase Heritage Common Shares for the aggregate gross proceeds of up to US\$20,000,000 by private placement, at Heritage's discretion (the "Offering"). On closing, the Company will pay the Investor an initial fee in an amount equal to 1.5% of US\$20,000,000, which will be satisfied by the issuance of Heritage Common Shares. An additional fee equal to 1.5% of US\$20,000,000 is due after 50% of the total Offering amount has been drawn by the Company, which amount may be satisfied by cash or the delivery of Heritage Common Shares at the option of the Company. The Company will also advance 79,030,611 Heritage Common Shares to the Investor in escrow (the "Escrow Shares"). The Escrow Shares will only be released to the Investor in tranches as and when the Company requests that the Investor purchase Heritage Common Shares pursuant to the ELOC Agreement. Any Escrow Shares that are not purchased by the Investor will be subject to cancellation at the end of the term of the ELOC Agreement.

(d) Issuance of common shares

On January 13, 2023, the Company issued 7,253,985 Heritage Common Shares as settlement of unpaid bonus of \$217,619, which was included in the accrued liabilities as at October 31, 2022.